"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,B2,US 8895597 B2,040-509-098-929-582,2014-11-25,2014,US 201113163223 A,2011-06-17,US 201113163223 A;;US 35582810 P,2010-06-17,Combination of local temozolomide with local BCNU,"The additive effect of combined intracranial carmustine (“BCNU”) with intracranial temozolomide (“TMZ”), and particularly in combination with radiation (“XRT”), in the treatment of two rat intracranial glioma models, the 9L gliosarcoma and the F98 glioma, demonstrates that local delivery of both drugs, especially in combination with radiation, is far more effective than delivery of either drug alone or one systemically and one locally, either with or without radiation. The triple therapy showed a significant improvement in survival when compared to controls (p=0.0004), local BCNU (p=0.0043), oral TMZ (p=0.0026), local TMZ (p=0.0105), and the combinations of either BCNU and XRT (p=0.0378) or oral TMZ and local BCNU (p=0.0154).",RECINOS VIOLETTE RENARD;;TYLER BETTY;;SUNSHINE SARAH BREM;;BREM HENRY,RECINOS VIOLETTE RENARD;;TYLER BETTY;;SUNSHINE SARAH BREM;;BREM HENRY,ACCELERATING COMBINATION THERAPIES LLC (2015-07-07),https://lens.org/040-509-098-929-582,Granted Patent,yes,14,0,2,2,0,A61K31/175;;A61K31/175;;A61K31/4188;;A61K31/495;;A61K31/495;;A61P35/00,A61K31/415;;A61K31/175;;A61K31/4188,514/393;;514/589,49,42,072-886-284-376-998;;150-238-557-334-294;;073-525-147-578-449;;077-254-000-049-52X;;014-817-761-035-764;;149-009-853-252-790;;062-330-808-123-937;;043-183-245-857-913;;063-850-777-436-505;;149-009-853-252-790;;015-213-731-536-495;;016-012-945-165-98X;;021-180-752-536-717;;019-264-483-343-031;;000-780-602-509-323;;139-708-175-669-908;;043-208-735-666-894;;072-886-284-376-998;;090-393-017-319-267;;077-254-000-049-52X;;030-423-548-321-209;;030-403-608-378-058;;112-454-797-947-768;;014-817-761-035-764;;043-957-258-447-792;;079-623-386-538-003;;081-023-162-918-931;;051-873-925-221-482;;055-042-922-753-043;;042-423-164-191-412;;075-879-471-313-54X;;013-984-845-044-117;;012-787-338-379-079;;098-337-997-673-45X;;181-746-063-671-034;;012-011-905-158-304;;004-590-480-892-122;;076-791-646-975-976;;015-485-848-898-966;;054-917-005-544-589;;042-615-128-075-402;;011-343-708-418-319,10.1215/s1522851700000703;;pmc1920622;;10.1093/neuonc/3.4.246;;11584894;;10.1215/15228517-3-4-246;;10.1093/annonc/mdi225;;15857844;;14769138;;pmc1871975;;10.1215/s1152851703000309;;pmc5217465;;10.1016/j.jconrel.2007.08.003;;17884232;;19046047;;pmc4856017;;10.3171/2008.5.17557;;10.1007/s00280-006-0407-2;;17256133;;10.1245/s10434-008-0048-2;;18636295;;446779;;10.1016/s0015-0282(16)44002-1;;6527243;;10.1002/jps.2600731215;;10.1007/s00280-006-0407-2;;17256133;;10.1016/s0140-6736(95)90755-6;;7723496;;8787853;;10.1007/bf01060217;;9766665;;12667889;;10.1016/s0163-7258(03)00014-7;;15687310;;10.1001/jama.293.5.557;;17108062;;pmc1828105;;10.1215/15228517-2006-024;;10.3171/jns.1992.76.4.0640;;1545259;;10.1215/s1522851700000703;;pmc1920622;;10.1093/neuonc/3.4.246;;11584894;;10.1215/15228517-3-4-246;;15014015;;10.1158/1078-0432.ccr-03-0174;;pmc5217465;;10.1016/j.jconrel.2007.08.003;;17884232;;pmc1968858;;8123472;;10.1038/bjc.1994.82;;2205908;;10.1016/0167-6989(87)90098-5;;19046047;;pmc4856017;;10.3171/2008.5.17557;;18389176;;10.1007/s11060-008-9576-7;;10.1097/00130404-200305000-00003;;12952300;;8033099;;15134485;;10.2174/1381612043384916;;10.1517/14712598.5.4.477;;15934827;;10.1227/01.neu.0000365263.14725.39;;20173548;;8781277;;10.1097/cad.0b013e32801476fd;;17762390;;11870182;;10.1200/jco.20.5.1375;;10.1200/jco.2002.20.5.1375;;10.1016/j.canrad.2005.05.001;;8417826;;9218294;;10.1097/00006123-199707000-00011;;10.1097/00001813-199701000-00013;;9147618;;10.1038/nmat1005;;14593392;;10.1215/s1522851702000236;;10.1093/neuonc/5.2.79;;pmc1920672;;12672279;;10.1215/15228517-5-2-79;;16482400;;10.1007/s00701-005-0707-z;;6690082;;10.1093/carcin/5.1.121;;10.1200/jco.1999.17.9.2762;;10561351,"Scott (thesis Jun. 16, 2010).Scott (thesis Jun. 16, 2010) (parts 1-3).;;Gururangan et al. (Neuro-Oncology 3, 246-250, 2001).;;National Institute for Clinical Excellence (Dec. 2004).;;Public Summary Document Nov. 2005.;;Prados (Semin Oncology 4(13); 24, 2001) Abstract Only.;;Barrie et al. (Annals of Oncology 16: 1177-1184, 2005).;;Prados et. al. (Neuro-Oncology p. 33-37, 2004).;;Kim et al (Journal of Controlled Release 123 (2007) 172-178).;;McGrit et al (J Neurosurg 110:583-588 (2009).;;Brem et al. (Cancer chemotherapy and Pharmacology, (2007) 60(5) 643-650).;;Gururangan et. al. (Neuro-Oncology 3, 246-250, 2001).;;Attenello, et al., ""Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience"", Ann Surg Oncol., 15:2887-93 (2008).;;Beck, et al., ""A new long-acting injectable microcapsule system for the administration of progesterone"", Fertil. Steril., 31:545 (1979).;;Benita, et al., ""Characterization of drug-loaded poly(d,l-lactide) microspheres"", J. Pharm. Sci., 73:1721 (1984).;;Brem, et al., ""Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model"",Cancer Chemother. Pharmacol., 60(5):643-650 (2007).;;Brem, et al., ""Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group"", Lancet, 345:1008-1012 (1995).;;Brem, et al. ""The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial"", J Neurooncol..26:111-123 (1995).;;Brock, et al., ""Phase I trial of temozolomide using an extended continuous oral schedule"", Cancer Res, 58:4363-4348 (1998).;;Castro, et al., ""Current and future strategies for the treatment of malignant brain tumors"", Pharmacal. Ther., 98(1):71-108 (2003).;;Chang, et al., ""Patterns of Care for Adults With Newly Diagnosed Malignant Glioma"", JAMA, 293(20):557-564 (2005).;;Gerber, et al., The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas Neuro Oncol, 9:47-52 (2007).;;Grossman, et al., ""The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers"", J. Neurosurg. 76(4):640-647 (1992).;;Gururangan, et al., ""Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas"", Neuro Oncol, 3:246-250 (2001).;;Hammond, et al., ""A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms"", Clin Cancer Res 10:1645-1656 (2004).;;Kim, et al., ""Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model"", J Control Release.,123(2):172-8 (2007).;;La Rocca, et al., ""A phase 2 study of multi-modal therapy with surgery, carmustine (BCNU) wafer, radiation therapy (RT), and temozolomide (TMZ) in patients (pts) with newly diagnosed supratentorial malignant glioma (MG)"", Presented at the 8th Congress of the European Association of Neurooncology, Barcellona, Spain, Sep. 12-14, 2008.;;Lee et al., ""Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide"", Br. J. Cancer 69:452-456 (1994).;;Mathiowitz, et al., ""Morphology of polyanhydride microsphere delivery systems"", J. Scanning Microscopy, 4:329 (1990).;;Mathiowitz, et al., ""Novel microcapsules for delivery Systems"", Reactive Polymers, 6:275-283(1987).;;McGirt, et al., ""Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme"" J Neurosurg, 110(3):583-588 (2009).;;Menei, et al., ""Biodegradable carmustine-impregnated wafers (Gliadel®): the French experience"". Presented at the 8th Congress of the European Association of Neurooncology, Barcellona, Spain, Sep. 12-14, 2008.;;Pan, et al. ""A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients"", J Neurooncol 88:353-357 (2008).;;Parney, et al., ""Current chemotherapy for glioblastoma"" Cancer J, 9:149-156 (2003),.;;Plowman, et al., ""Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea"", Cancer Res, 54:3793-99 (1994).;;Rautio, et al, ""Drug delivery systems for brain tumor therapy"", Curr Pharm Des, 10:1341-1353 (2004).;;Raza, et al., ""Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours"", Expert Opin. Biol. Ther., 5(4):477-494 (2005).;;Recinos, at al., ""Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model"", Neurosurgery, 66:530-37 (2010).;;Rostomily, et al., ""Radical surgery in the management of low-grade and high-grade gliomas"", Baillieres Clin Neurol, 5:345-369 (1996).;;Soffietti, et al., ""New chemotherapy options for the treatment of malignant gliomas"", Anticancer Drugs, 18:621-632 (2007).;;Stupp, et al., ""Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide"", J Clin Oncol, 20:1375-1382 (2002).;;Stupp, et al, ""Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma"", N Engl J Med 352:987-996 (2005).;;Tamargo, et al, ""Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain"", Cancer Res. 53(2):329-333 (1993).;;Valtonen, et al., ""Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study"", Neurosurgery 41:44-48 (1997).;;Wedge, et al., ""In vitro evaluation of temozolomide combined with X-irradiation"", Anticancer Drugs, 8:92-97 (1997).;;West, ""Drug delivery: pulsed polymers"", Nat Mater., 2(11):709-10 (2003).;;Westphal, et al., ""A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma"", Neuro Oncol 5:79-88 (2003).;;Westphal, et al., ""Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial"", Acta Neurochir (Wien), 148:269-275 (2006).;;Wiestler, et al., ""O6-alkylguanine-DNA alkyltransferase activity in human brain and brain tumors"", Carcinogenesis, 5:121-124 (1984).;;Yung, et al., ""Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group"" , J Clin Oncol ,17:2762-2771 (1999).",ACTIVE
2,US,A1,US 2011/0313010 A1,159-139-784-576-035,2011-12-22,2011,US 201113163223 A,2011-06-17,US 201113163223 A;;US 35582810 P,2010-06-17,COMBINATION OF LOCAL TEMOZOLOMIDE WITH LOCAL BCNU,"The additive effect of combined intracranial carmustine (“BCNU”) with intracranial temozolomide (“TMZ”), and particularly in combination with radiation (“XRT”), in the treatment of two rat intracranial glioma models, the 9L gliosarcoma and the F98 glioma, demonstrates that local delivery of both drugs, especially in combination with radiation, is far more effective than delivery of either drug alone or one systemically and one locally, either with or without radiation. The triple therapy showed a significant improvement in survival when compared to controls (p=0.0004), local BCNU (p=0.0043), oral TMZ (p=0.0026), local TMZ (p=0.0105), and the combinations of either BCNU and XRT (p=0.0378) or oral TMZ and local BCNU (p=0.0154).",RECINOS VIOLETTE RENARD;;TYLER BETTY;;SUNSHINE SARAH BREM;;BREM HENRY,RECINOS VIOLETTE RENARD;;TYLER BETTY;;SUNSHINE SARAH BREM;;BREM HENRY,ACCELERATING COMBINATION THERAPIES LLC (2015-07-07),https://lens.org/159-139-784-576-035,Patent Application,yes,1,4,2,2,0,A61K31/175;;A61K31/175;;A61K31/4188;;A61K31/495;;A61K31/495;;A61P35/00,A61K31/4188;;A61K31/175;;A61P35/00,514/393;;514/589,11,6,072-886-284-376-998;;150-238-557-334-294;;073-525-147-578-449;;077-254-000-049-52X;;014-817-761-035-764;;149-009-853-252-790,10.1215/s1522851700000703;;pmc1920622;;10.1093/neuonc/3.4.246;;11584894;;10.1215/15228517-3-4-246;;10.1093/annonc/mdi225;;15857844;;14769138;;pmc1871975;;10.1215/s1152851703000309;;pmc5217465;;10.1016/j.jconrel.2007.08.003;;17884232;;19046047;;pmc4856017;;10.3171/2008.5.17557;;10.1007/s00280-006-0407-2;;17256133,"Scott (thesis Jun 16 2010).Scott (thesis Jun 16 2010) (parts 1-3).;;Gururangan et al. (Neuro-Oncology 3, 246-250, 2001).;;National Institute For Clinical Excellence (December 2004).;;Public Summary Document November 2005;;Prados (Semin Oncology 4(13); 24, 2001) Abstract Only.;;Barrie et al. (Annals of Oncology 16: 1177-1184, 2005).;;Prados et. al. (Neuro-Oncology pg 33-37, 2004);;Kim et al (Journal of Controlled Release 123 (2007) 172-178);;McGrit et al (J Neurosurg 110:583-588 (2009);;Brem et al. (Cancer chemotherapy and Pharmacology, (2007) 60(5) 643-650)..;;Gururangan et. al. (Neuro-Oncology 3, 246-250, 2001)",ACTIVE
3,DE,T2,DE 69534080 T2,068-015-259-706-483,2006-04-13,2006,DE 69534080 T,1995-08-02,US 28434194 A;;US 9509805 W,1994-08-02,"KONTROLLIERTE, LOKALE VERABREICHUNG VON CHEMOTHERAPEUTISCHEN WIRKSTOFFEN ZUR BEHANDLUNG VON FESTEN TUMOREN",,MASSACHUSETTS INST TECHNOLOGY;;UNIV JOHNS HOPKINS,BREM HENRY;;LANGER J;;DOMB J,,https://lens.org/068-015-259-706-483,Granted Patent,no,0,0,15,16,0,A61K9/0085;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/337;;A61K31/4745;;A61K31/555;;A61P35/00;;A61K9/0085;;A61K31/337;;A61K31/4745;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/555,A61K31/28;;A61K9/00;;A61K9/20;;A61K9/22;;A61K31/282;;A61K31/335;;A61K31/337;;A61K31/47;;A61K31/4745;;A61K38/00;;A61K39/395;;A61K45/00;;A61K47/34;;A61P35/00,,0,0,,,,EXPIRED
4,DE,D1,DE 69534080 D1,118-954-020-186-065,2005-04-21,2005,DE 69534080 T,1995-08-02,US 28434194 A;;US 9509805 W,1994-08-02,"KONTROLLIERTE, LOKALE VERABREICHUNG VON CHEMOTHERAPEUTISCHEN WIRKSTOFFEN ZUR BEHANDLUNG VON FESTEN TUMOREN",,MASSACHUSETTS INST TECHNOLOGY;;UNIV JOHNS HOPKINS,BREM HENRY;;LANGER J;;DOMB J,,https://lens.org/118-954-020-186-065,Granted Patent,no,0,0,15,16,0,A61K9/0085;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/337;;A61K31/4745;;A61K31/555;;A61P35/00;;A61K9/0085;;A61K31/337;;A61K31/4745;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/555,A61K9/00;;A61K9/20;;A61K9/22;;A61K31/282;;A61K31/337;;A61K31/47;;A61K31/4745;;A61K38/00;;A61K39/395;;A61K45/00;;A61K47/34,,0,0,,,,EXPIRED
5,US,A1,US 2023/0416746 A1,036-218-454-498-375,2023-12-28,2023,US 202118037482 A,2021-11-18,US 202118037482 A;;US 202063115803 P;;US 202163246146 P;;US 2021/0059900 W,2020-11-19,IMMUNO-ONCOLOGY TARGETS TO IMPROVE T-CELL METABOLIC RESPONSE,"The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods utilizing Meteorin-like (METRNL), C-X-C Motif Chemokine Receptor 6 (CXCR6) and/or endogenous C-X-C Motif Ligand 16 (CXCL16) as immune-oncology targets. Accordingly, in one aspect, the present invention provides compositions and methods directed to the knockout of METRNL, CXCR6 and/or CXCL16 expression in a cell. In particular embodiments, the cell is a T cell. In a specific embodiment, the present invention provides an engineered T-cell comprising disruption in the METRNL, CXCR6 and/or CXCL16 gene sequence. In another embodiment, an engineered T-cell comprises (a) at least one chimeric antigen receptor (CAR); and (b) at least one genomic disruption of METRNL, CXCR6 and/or CXCL16. In certain embodiments, the genomic disruption is performed using a CRSIPR endonuclease system.",UNIV JOHNS HOPKINS,LIM MICHAEL;;JACKSON CHRISTOPHER;;PANT AYUSH;;BREM HENRY,,https://lens.org/036-218-454-498-375,Patent Application,yes,0,0,3,3,1,A61P35/00;;C12N15/1136;;C12N2310/20;;C12N2310/14;;C12N15/1138;;C12N5/0636;;C12N2501/20;;C12N2510/00;;A61K31/7105;;A61K31/713;;A61P37/06;;A61K39/4611;;A61K39/4631;;C07K16/2866;;C12N15/1136;;C12N2310/11;;C12N2310/12;;C12N2310/14;;C12N2310/531,C12N15/113;;A61K39/00;;A61P37/06;;C07K16/28,,0,0,,,,PENDING
6,WO,A1,WO 2022/109141 A1,097-413-601-242-588,2022-05-27,2022,US 2021/0059900 W,2021-11-18,US 202063115803 P;;US 202163246146 P,2020-11-19,IMMUNO-ONCOLOGY TARGETS TO IMPROVE T-CELL METABOLIC RESPONSE,"The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods utilizing Meteorin-like (METRNL), C-X-C Motif Chemokine Receptor 6 (CXCR6) and/or endogenous C-X-C Motif Ligand 16 (CXCL16) as immune-oncology targets. Accordingly, in one aspect, the present invention provides compositions and methods directed to the knockout of METRNL, CXCR6 and/or CXCL16 expression in a cell. In particular embodiments, the cell is a T cell. In a specific embodiment, the present invention provides an engineered T-cell comprising disruption in the METRNL, CXCR6 and/or CXCL16 gene sequence. In another embodiment, an engineered T-cell comprises (a) at least one chimeric antigen receptor (CAR); and (b) at least one genomic disruption of METRNL, CXCR6 and/or CXCL16. In certain embodiments, the genomic disruption is performed using a CRSIPR endonuclease system.",UNIV JOHNS HOPKINS,LIM MICHAEL;;JACKSON CHRISTOPHER;;PANT AYUSH;;BREM HENRY,,https://lens.org/097-413-601-242-588,Patent Application,yes,4,0,3,3,0,A61P35/00;;C12N15/1136;;C12N2310/20;;C12N2310/14;;C12N15/1138;;C12N5/0636;;C12N2501/20;;C12N2510/00;;A61K31/7105;;A61K31/713;;A61P37/06;;A61K39/4611;;A61K39/4631;;C07K16/2866;;C12N15/1136;;C12N2310/11;;C12N2310/12;;C12N2310/14;;C12N2310/531,A61K31/7052;;C12N5/0783;;A61K31/7088;;A61P35/00;;C12N15/117,,3,2,052-836-308-155-727;;111-326-193-579-498,10.1155/2015/794528;;pmc4668311;;26665011;;10.2147/jir.s270872;;33061527;;pmc7532903,"IRINA USHACH, GERARDO ARREVILLAGA-BONI, GINA N. HELLER, EGEST PONE, MARCELA HERNANDEZ-RUIZ, JOVANI CATALAN-DIBENE, PETER HEVEZI, A: ""Meteorin-like/Meteorin-β Is a Novel Immunoregulatory Cytokine Associated with Inflammation"", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO., US, vol. 201, no. 12, 15 December 2018 (2018-12-15), US , pages 3669 - 3676, XP055645756, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1800435;;MEGAN A. MCNAMARA, SMITA K. NAIR, EDA K. HOLL: ""RNA-Based Vaccines in Cancer Immunotherapy"", JOURNAL OF IMMUNOLOGY RESEARCH, HINDAWI PUBLISHING CORPORATION, US, vol. 2015, 1 January 2015 (2015-01-01), US , pages 1 - 9, XP055391143, ISSN: 2314-8861, DOI: 10.1155/2015/794528;;DHAIBAN SARAH, AL-ANI MENA, ELEMAM NOHA MOUSAAD, MAGHAZACHI AZZAM A: ""Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis"", JOURNAL OF INFLAMMATION RESEARCH, vol. Volume 13, 29 September 2020 (2020-09-29), pages 619 - 633, XP055940057, DOI: 10.2147/JIR.S270872",PENDING
7,PT,E,PT 774964 E,135-846-078-400-819,2005-08-31,2005,PT 95928721 T,1995-08-02,US 28434194 A,1994-08-02,ENTREGA LOCAL CONTROLADA DE AGENTES QUIMIOTERAPEUTICOS PARA TRATAMENTO DE TUMORES SOLIDOS,,MASSACHUSETTS INST TECHNOLOGY;;UNIV JOHNS HOPKINS,HENRY BREM;;LANGER ROBERT J;;DOMB ABRAHAM J,,https://lens.org/135-846-078-400-819,Granted Patent,no,0,0,15,16,0,A61K9/0085;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/337;;A61K31/4745;;A61K31/555;;A61P35/00;;A61K9/0085;;A61K31/337;;A61K31/4745;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/555,A61K9/00;;A61K9/20;;A61K9/22;;A61K31/282;;A61K31/337;;A61K31/47;;A61K31/4745;;A61K38/00;;A61K39/395;;A61K45/00;;A61K47/34,,0,0,,,,EXPIRED
8,DK,T3,DK 0774964 T3,042-319-521-525-485,2005-07-25,2005,DK 95928721 T,1995-08-02,EP 95928721 A;;US 9509805 W;;US 28434194 A,1994-08-02,Kontrolleret lokal tilförsel af kemoterapeutiske midler til behandling af faste tumorer,,MASSACHUSETTS INST TECHNOLOGY;;UNIV JOHNS HOPKINS,DOMB ABRAHAM J;;BREM HENRY;;LANGER ROBERT J,,https://lens.org/042-319-521-525-485,Granted Patent,no,0,0,1,16,0,,A61K9/00;;A61K9/20;;A61K31/28;;A61K31/335;;A61K31/47;;A61K47/34;;A61P35/00,,0,0,,,,EXPIRED
9,AT,T1,AT E290860 T1,113-757-824-167-084,2005-04-15,2005,AT 95928721 T,1995-08-02,US 28434194 A;;US 9509805 W,1994-08-02,"KONTROLLIERTE, LOKALE VERABREICHUNG VON CHEMOTHERAPEUTISCHEN WIRKSTOFFEN ZUR BEHANDLUNG VON FESTEN TUMOREN",,MASSACHUSETTS INST TECHNOLOGY;;UNIV JOHNS HOPKINS,BREM HENRY;;LANGER ROBERT J;;DOMB ABRAHAM J,,https://lens.org/113-757-824-167-084,Granted Patent,no,0,0,15,16,0,A61K9/0085;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/337;;A61K31/4745;;A61K31/555;;A61P35/00;;A61K9/0085;;A61K31/337;;A61K31/4745;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/555,A61K9/00;;A61K9/20;;A61K9/22;;A61K31/282;;A61K31/337;;A61K31/47;;A61K31/4745;;A61K38/00;;A61K39/395;;A61K45/00;;A61K47/34,,0,0,,,,DISCONTINUED
10,AU,A,AU 1992/014119 A,133-458-357-480-99X,1992-08-27,1992,AU 1992/014119 A,1992-01-15,US 64149891 A,1991-01-15,A COMPOSITION CONTAINING A TETRACYCLINE AND USE FOR INHIBITING ANGIOGENESIS,,BREM HENRY,BREM HENRY;;TAMARGO RAFAEL J;;BOK ROBERT A,,https://lens.org/133-458-357-480-99X,Patent Application,no,0,0,4,4,0,A61K31/65;;A61K31/675;;A61K31/70;;A61K31/715;;A61K38/04;;A61K31/70;;A61K31/65;;A61K31/675;;A61K31/715;;A61K38/04,A61K31/65;;A61K31/675;;A61K31/715;;A61K38/04,,0,0,,,,PENDING
11,CA,C,CA 2196304 C,029-476-977-554-936,2011-02-15,2011,CA 2196304 A,1995-08-02,US 28434194 A;;US 9509805 W,1994-08-02,CONTROLLED LOCAL DELIVERY OF CHEMOTHERAPEUTIC AGENTS FOR TREATING SOLID TUMORS,"A method and devices for localized delivery of a chemotherapeutic agent to solid tumors, wherein the agent does not cross the blood--brain barrier and is characterized by poor bioavailability and/or short half-lives in vivo, are described. The devices consist of reservoirs which release drug over an extended time period while at the same time preserving the bioactivity and bioavailability of the agent. In the most preferred embodiment, the device consists of biodegradable polymeric matrixes, although reservoirs can also be formulated from non--biodegradable polymers or reservoirs connected to implanted infusion pumps. The devices are implanted within or immediately adjacent the tumors to be treated or the site where they have been surgically removed. The examples demonstrate the efficacy of paclitaxel, camptothecin, and carboplatin delivered in polymeric implants prepared by compression molding of biodegradable and non-biodegradable polymers, respectively. The results are highly statistically significant.",MASSACHUSETTS INST TECHNOLOGY;;UNIV JOHNS HOPKINS,BREM HENRY;;LANGER ROBERT S;;DOMB ABRAHAM J,,https://lens.org/029-476-977-554-936,Granted Patent,no,0,0,15,16,0,A61K9/0085;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/337;;A61K31/4745;;A61K31/555;;A61P35/00;;A61K9/0085;;A61K31/337;;A61K31/4745;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/555,A61K47/34;;A61K9/00;;A61K9/20;;A61K9/22;;A61K31/282;;A61K31/337;;A61K31/47;;A61K31/4745;;A61K38/00;;A61K39/395;;A61K45/00,,0,0,,,,EXPIRED
12,WO,A3,WO 1992/012717 A3,150-027-140-849-356,1992-10-15,1992,US 9200254 W,1992-01-15,US 64149891 A,1991-01-15,A COMPOSITION CONTAINING A TETRACYCLINE AND USE FOR INHIBITING ANGIOGENESIS,,BREM HENRY;;TAMARGO RAFAEL J;;BOK ROBERT A,BREM HENRY;;TAMARGO RAFAEL J;;BOK ROBERT A,,https://lens.org/150-027-140-849-356,Search Report,no,6,0,4,4,0,A61K31/65;;A61K31/675;;A61K31/70;;A61K31/715;;A61K38/04;;A61K31/70;;A61K31/65;;A61K31/675;;A61K31/715;;A61K38/04,A61K31/65;;A61K31/675;;A61K31/715;;A61K38/04,,8,6,001-048-038-533-697;;113-133-332-757-226;;019-335-576-148-708;;110-443-128-308-33X;;014-455-106-532-523;;052-025-388-218-214,10.1093/jnci/75.3.517;;2993728;;1965517;;10.1177/10454411910020030201;;1654139;;1702361;;10.1002/ijc.2910350420;;2580804;;2455830,"JNCI, vol. 75, no. 3, September 1985, S. ZUCKER et al.: ""Diversity of melanoma plasma membrane proteinases: Inhibition of collagenolytic and cytolytic activities by minocycline"", pages 517-527, see abstract; pages 517,521 - end of article (cited in the application);;Research Communications in Chemical Pathology and Pharmacology, vol. 70, no. 3, December 1990, N.S. RAMAMURTHY et al.: ""The effect of tetracyclines on collagenase activity in UMR 106-01 rat osteoblastic osteosarcoma cells"", pages 323-335, see abstract; pages 330-333: ""Discussion"";;Critical Reviews in Oral Biology and Medicine, vol. 2, no. 2, 26 August 1991, L.M. GOLUB et al.: ""Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs"", pages 297-321, see abstract; pages 298,299,302,313-315 (cited in the application);;Cancer Research, vol. 51, no. 2, 15 January 1991, R.J. TAMARGO et al.: ""Angiogenesis inhibition by minocycline"", pages 672-675, see abstract; pages 672-674;;Database WPIL, accession no. 88-024373 [04], Derwent Publications Ltd, London, GB, & JP,A,62283921 (KAO CORP.) 09-12-1987, see abstract;;Drugs under Experimental and Clinical Research, vol. 10, no. 11, 1984, A.M. KROON et al.: ""The antitumor action of doxycycline"", pages 759-766, see summary;;International Journal of Cancer, vol. 35, no. 4, 15 April 1985, M. ZICHE et al.: ""Effects of cortisone with and without heparin on angiogenesis induced by prostaglandin E1 and by S180 cells and on growth of murine transplantable tumours"", pages 549-552, see abstract; pages 549,551;;Laboratory Investigation, vol. 59, no. 1, July 1988, D. INGBER et al.: ""Inhibition of angiogenesis through modulation of collagen metabolism"", pages 44-51, see abstract; pages 44,49,50 (cited in the application)",PENDING
13,US,A,US 5626862 A,032-573-384-041-505,1997-05-06,1997,US 28434194 A,1994-08-02,US 28434194 A,1994-08-02,Controlled local delivery of chemotherapeutic agents for treating solid tumors,"A method and devices for localized delivery of a chemotherapeutic agent to solid tumors, wherein the agent does not cross the blood-brain barrier and is characterized by poor bioavailability and/or short half-lives in vivo, are described. The devices consist of reservoirs which release drug over an extended time period while at the same time preserving the bioactivity and bioavailability of the agent. In the most preferred embodiment, the device consists of biodegradable polymeric matrixes, although reservoirs can also be formulated from non-biodegradable polymers or reservoirs connected to implanted infusion pumps. The devices are implanted within or immediately adjacent the tumors to be treated or the site where they have been surgically removed. The examples demonstrate the efficacy of paclitaxel and camptothecin delivered in polymeric implants prepared by compression molding of biodegradable and non-biodegradable polymers, respectively. The results are highly statistically significant.",MASSACHUSETTS INST TECHNOLOGY;;UNIV JOHNS HOPKINS,BREM HENRY;;LANGER ROBERT S;;DOMB ABRAHAM J,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1994-08-25);;JOHNS HOPKINS UNIVERSITY THE (1994-10-01),https://lens.org/032-573-384-041-505,Granted Patent,yes,12,418,15,16,0,A61K9/0085;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/337;;A61K31/4745;;A61K31/555;;A61P35/00;;A61K9/0085;;A61K31/337;;A61K31/4745;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/555,A61K9/00;;A61K9/20;;A61K9/22;;A61K31/282;;A61K31/337;;A61K31/47;;A61K31/4745;;A61K38/00;;A61K39/395;;A61K45/00;;A61K47/34,424/426;;424/1.11;;424/425,42,31,036-244-095-637-781;;019-632-131-954-732;;013-995-282-147-422;;070-454-750-275-448;;024-006-980-622-786;;091-270-113-628-795;;082-889-728-774-054;;043-208-735-666-894;;038-557-791-213-931;;009-808-542-361-708;;072-881-723-835-410;;005-700-462-255-016;;041-753-324-074-713;;128-901-299-587-74X;;081-856-693-634-846;;030-086-684-551-442;;027-020-025-969-407;;066-908-971-655-179;;026-597-070-691-440;;032-005-116-883-006;;061-524-103-412-631;;137-444-228-901-75X;;027-487-596-441-939;;047-934-567-231-104;;041-027-996-169-911;;048-474-777-036-86X;;000-432-869-166-402;;011-192-705-650-782;;038-122-231-289-716;;181-746-063-671-034;;012-874-732-218-113,10.1023/a:1018943021705;;7909371;;10.1159/000152408;;4332744;;10.3171/jns.1991.74.3.0441;;1993909;;10.1097/00005072-198107000-00005;;7252525;;10.1002/pola.1987.080251217;;5030802;;4946015;;10.3171/jns.1992.76.4.0640;;1545259;;10.1097/00001813-199204000-00008;;1356030;;10.1111/j.1749-6632.1986.tb38455.x;;2873780;;2993532;;10.1097/00005072-198509000-00003;;1686489;;10.3928/1542-8877-19911101-11;;10.1038/263797a0;;995197;;10.1002/jbm.820150212;;7348718;;10.1002/jbm.820190806;;3880353;;10.1002/jbm.820200106;;3949823;;5030811;;5081595;;10.1002/jps.2600690305;;7189778;;2886648;;6860755;;10.1016/0142-9612(83)90054-6;;10.1002/1097-0142(197806)41:6<2305::aid-cncr2820410632>3.0.co;2-u;;657095;;2898289;;2568175;;10.1093/jnci/82.15.1247;;1973737;;2889203;;10.1002/pros.2990110112;;10.1097/00006123-199110000-00007;;1944832;;8103561;;pmc2571868;;10.1002/j.1552-4604.1990.tb01873.x;;1980498;;8417826;;10.1007/bf00151247;;2022973,"Walter et al., Chem. Abs . 120(22), 280088 (May 30, 1994).;;Kaetsu et al., Chem. Abs . 108(22) 192636 (May 30, 1988).;;Straw et al., Chem. Abs . 121(20), 238234 (Nov. 14, 1994).;;Auerbach et al., Chem. Abs . 121(1), 159 (Jul. 4, 1994).;;Alkan Onyuksel, Hayat, et al., A Mixed Micellar Formulation Suitable for the Parenteral Administration of Taxol, Pharm. Res . 11(2):206 212 (1994).;;Beckman, G., et al., G 6 PD and PGM Phenotypes of 16 Continuous Human Tumor Cell Lines, Hum. Hered . 21:238 241 (1971).;;Brem, Henry, et al., Polymers as Controlled Drug Delivery Devices for the Treatment of Malignant Brain Tumors, Eur. J. Pharm. Biopharm . 39(1):2 7 (1993).;;Brem, Henry, et al., Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas, J. Neurosurg . 74:441 446 (1991).;;Brem, Henry, et al., Intraoperative Chemotherapy using biodegradable polymers: Safety and Effectiveness for Recurrent Glioma Evaluated by a Prospective, Multi Institutional Placebo Controlled Clinical Trail, Proc. Amer. Soc. Clin. Oncology May 17, 1994.;;Bullard, Dennis E., et al., Growth and Chemotherapeutic Response in Athymic Mice of Tumors Arising from Human Glioma derived Cell Lines, J. Neuropathol. Exp. Neurol . 40:410 427 (1981).;;Domb, A.J. and R. Langer, Polyanhydrides. I. Preparation of High Molecular Weight Polyanhydrides, J. Polym. Sci . 25:3373 3386 (1987).;;Domb, et al., In Vitro Release Kinetics Studies, Polym. Prepr . 32(2):219 220 (1991).;;Gottlieb, Jeffrey A., and James K. Luce, Treatment of Malignant Melanoma With Camptothecin (NSC 100880), Cancer Chemother. Rep . 56(1):103 105 (1972).;;Gottlieb, Jeffrey A., et al., Preliminary Pharmacologic and Clinical Evaluation of Camptothecin Sodium (NSC 100880), Cancer Chemother. Rep . 54(6):461 470 (1970).;;Grossman, Stuart, et al., The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers, J. Neurosurg . 76:640 647 (1992).;;Hanauske, Axel R., et al., Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells, Anticancer Drugs 3:121 124 (1992).;;Harrison s Principles of Internal Medicine 431 446, E. Braunwald et al., ed., McGraw Hill Book Co. (1987).;;Horwitz, S.B., et al., Taxol: Mechanisms of Action and Resistance, Ann. NY Acad. Sci . 466:733 744 (1986).;;Jacobsen, P.F., et al., Establishment of a Human Medulloblastoma Cell Line and Its Heterotransplantation into Nude Mice, J. Neuropathol. Exp. Neurol . 44:472 485 (1985).;;Jampel, Henry D., and Paroo Koya, In Vitro Release of Hydrophobic Drugs From Polyanhydride Disks, Opthalmic Surg . 22,676 680 (1991).;;Klecker, R.W., et al., Distribution and metabolism of 3 H taxol in the rat, Proc. Am. Assoc. Cancer Res . 43:380 (1993).;;Langer, Robert and Judah Folkman, Polymers for the sustained release of proteins and other macromolecules, Nature ( London ) 263:797 799 (1976).;;Langer, Robert, et al., Biocompatibility of polymeric delivery systems for macromolecules, J. Biomed. Mater. Res . 15:267 277 (1981).;;Leong, K.W., et al., Bioerodible polyanhydrides as drug carrier matrices. I: Characterization, degradation, and release characteristics, J. Med. Biomed. Mater. Res . 19:941 (1985).;;Leong, K.W., et al. Bioerodible polyanhydrides as drug carrier matrices. II. Biocompatibility and chemical reactivity, J. Med. Biomed. Mater. Res . 20:51 (1986).;;Moertel, Charles G., et al., Phase II Study of Camptothecin (NSC 100880) in the Treatment of Advanced Gastrointestinal Cancer, Cancer Chemother. Rep . 56(1):95 101 (1972).;;Muggia, Franco M., et al., Phase I Clinical Trial Weekly and Daily Treatment with Camptothecin (NSC 100880): Correlation with Preclinical Studies, Cancer Chemother. Rep . 56(4):515 521 (1972).;;Rhine, William D., et al., Polymers for Sustained Macromolecule Release: Procedures to Fabricate Reproducible Delivery Systems and Control Release Kinetics, J. Pharm. Sci . 69:265 270 (1980).;;Ringel, Israel, and Susan Band Horwitz, Taxol is Converted to 7 Epitaxol, a Biologically Active Isomer, in Cell Culture Medium, J. Pharmacol. Exp. Ther . 242:692 698 (1987).;;Rosen, H.B., et al., Bioerodible polyanhydrides for controlled drug delivery, Biomaterials 4:131 (1983).;;Rosenblum, Mark L., et al., Development of a Clonogenic Cell Assay for Human Brain Tumors, Cancer 41:2305 2314 (1978).;;Roth, B., et al., Taxol (NSC 125973) in Advanced, Hormone Refractory Prostrate Cancer: An Ecog Phase II Trail, Pr. Annu. Meet. Am. Soc. Clin. Oncol . 11:A598 (1992).;;Rowinsky, Eric K., et al., Microtubule Chanes and Cytotoxicity in Leukemic Cell Lines Treated with Taxol, Cancer Res . 48:4093 4100 (1988).;;Rowinsky, Eric K., et al., Phase I and Pharmacodynamic Study of Taxol in Refractory Acute Leukemias, Cancer Res . 49:4640 4647 (1989).;;Rowinsky, Eric K., et al., Taxol: A Novel Investigational Antimicrotubule Agent, J. Natl. Cancer Inst . 82:1247 1259 (1990).;;Roytta, Matias, et al., Morphological Studies on the Effect of Taxol on Cultured Human Prostatic Cancer Cells, Prostate 11:95 106 (1987).;;Salcman, Michael, et al., In Vitro Response of Human Glioblastoma and Canine Glioma Cells to Hyperthermia, Radiation, and Chemotherapy, Neurosurgery 29:526 531 (1991).;;Sarosy, Gisele and Eddie Reed, Taxol Dose Intensification and Its Clinical Implications, J. Nat. Med. Assoc . 85(6):427 431 (1993).;;Slichenmyer, William J., et al., New Natural Products in Cancer Chemotherapy, J. Clin. Pharmacol . 30:770 788 (1990).;;Tamargo, Rafael J., et al. Interstitial Chemotherapy of the 9L Gliosarcoma: Controlled Release Polymers for Drug Delivery in the Brain, Cancer Res . 53:329 333 (1993).;;Tamita, T., Interstitial chemotherapy for brain tumors: review J. Neuro Oncology 10:57 74 (1991).;;Venditti, John M., and Betty J. Abbott, Studies on Oncolytic Agents from Natural Sources, Correlations of Activity Against Animal Tumors and Clinical Effectiveness, Lloydia 30:332 348 (1967).",EXPIRED
14,US,B1,US 6482810 B1,060-529-131-796-35X,2002-11-19,2002,US 22710094 A,1994-04-13,US 22710094 A;;US 64149891 A,1991-01-15,Antibiotic composition for inhibition of angiogenesis,"
    Pharmaceutical compositions for delivering an effective dose of an angiogenesis inhibitor consisting of a tetracycline or tetracycline such as minocycline. The effective dosage for inhibition of angiogenesis based on in vitro testing is between one and 500 micromolar. The compositions are delivered topically, locally or systemically using implants or injection. The composition is extremely selective for growth of endothelial cells, inhibiting growth, but is not cytotoxic at the effective dosages. 
",BREM HENRY;;TAMARGO RAFAEL J.;;BOK ROBERT A.,BREM HENRY;;TAMARGO RAFAEL J;;BOK ROBERT A,,https://lens.org/060-529-131-796-35X,Granted Patent,yes,1,80,4,4,0,A61K31/65;;A61K31/675;;A61K31/70;;A61K31/715;;A61K38/04;;A61K31/70;;A61K31/65;;A61K31/675;;A61K31/715;;A61K38/04,A61K31/65;;A61K31/675;;A61K31/715;;A61K38/04,514/152,2,1,120-257-136-838-545,10.1016/s0304-3835(84)80023-3;;6518450,"Kroon et al, Cancer Letters, vol. 25 1984 pp. 33-40.*;;Kroon et al, Drugs Expl. clim. Res, vol. 11, 1984, pp. 759-766.",EXPIRED
15,US,A,US 5651986 A,075-106-126-960-717,1997-07-29,1997,US 66371196 A,1996-06-14,US 66371196 A;;US 28434194 A,1994-08-02,Controlled local delivery of chemotherapeutic agents for treating solid tumors,"A method and devices for localized delivery of a chemotherapeutic agent to solid tumors, wherein the agent does not cross the blood-brain barrier and is characterized by poor bioavailability and/or short half-lives in vivo, are described. The devices consist of reservoirs which release drug over an extended time period while at the same time preserving the bioactivity and bioavailability of the agent. In the most preferred embodiment, the device consists of biodegradable polymeric matrixes, although reservoirs can also be formulated from non-biodegradable polymers or reservoirs connected to implanted infusion pumps. The devices are implanted within or immediately adjacent the tumors to be treated or the site where they have been surgically removed. The examples demonstrate the efficacy of paclitaxel and camptothecin delivered in polymeric implants prepared by compression molding of biodegradable and non-biodegradable polymers, respectively. The results are highly statistically significant.",MASSACHUSETTS INST TECHNOLOGY;;UNIV JOHNS HOPKINS,BREM HENRY;;LANGER ROBERT S;;DOMB ABRAHAM J,,https://lens.org/075-106-126-960-717,Granted Patent,yes,1,254,15,16,0,A61K9/0085;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/337;;A61K31/4745;;A61K31/555;;A61P35/00;;A61K9/0085;;A61K31/337;;A61K31/4745;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/555,A61K9/00;;A61K9/20;;A61K9/22;;A61K31/282;;A61K31/337;;A61K31/47;;A61K31/4745;;A61K38/00;;A61K39/395;;A61K45/00;;A61K47/34,424/484;;424/401;;424/426;;424/486;;424/499,0,0,,,,EXPIRED
16,ES,T3,ES 2243940 T3,023-661-827-890-738,2005-12-01,2005,ES 95928721 T,1995-08-02,US 28434194 A,1994-08-02,LIBERACION LOCAL CONTROLADA DE UN AGENTE QUIMIOTERAPEUTICO PARA EL TRATAMIENTO DE TUMORES SOLIDOS.,"SE DESCRIBE UN METODO Y DISPOSITIVOS PARA EL SUMINISTRO LOCALIZADO DE UN AGENTE QUIMIOTERAPEUTICO A TUMORES SOLIDOS, DE FORMA QUE EL AGENTE NO TRASPASA LA BARRERA SANGUINEA CEREBRAL Y SE CARACTERIZA POR UNA ESCASA BIODISPONIBILIDAD Y/O CORTAS SEMIVIDAS IN VIVO. LOS DISPOSITIVOS CONSISTEN EN RESERVORIOS QUE LIBERAN MEDICACION DURANTE UN PERIODO PROLONGADO DE TIEMPO MIENTRAS QUE AL MISMO TIEMPO SE PRESERVA LA BIOACTIVIDAD Y BIODISPONIBILIDAD DEL AGENTE. EN LA VERSION MAS PREFERIDA, EL DISPOSITIVO CONSISTE DE MATRICES POLIMERICAS BIODEGRADABLES, AUNQUE TAMBIEN SE PUEDEN FORMULAR RESERVORIOS DE POLIMEROS NO BIODEGRADABLES O RESERVORIOS EN CONEXION CON BOMBAS DE INFUSION IMPLANTADAS. LOS DISPOSITIVOS SE IMPLANTAN DENTRO O INMEDIATAMENTE CERCA DE LOS TUMORES A TRATAR O DEL SITIO DE DONDE HAN SIDO RETIRADOS QUIRURGICAMENTE. LOS EJEMPLOS DEMUESTRAN LA EFICACIA DE PACLITAXEL, CAMPTOTECINA Y CARBOPLATINO SUMINISTRADOS EN IMPLANTES POLIMERICOS PREPARADOS MEDIANTE MOLDEADO POR COMPRESION DE POLIMEROS BIODEGRADABLES Y NO BIODEGRADABLES, RESPECTIVAMENTE. LOS RESULTADOS SON SIGNIFICATIVA Y ALTAMENTE SATISFACTORIOS.",MASSACHUSETTS INST TECHNOLOGY;;UNIV JOHNS HOPKINS,BREM HENRY;;LANGER ROBERT J;;DOMB ABRAHAM J,,https://lens.org/023-661-827-890-738,Granted Patent,no,0,0,15,16,0,A61K9/0085;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/337;;A61K31/4745;;A61K31/555;;A61P35/00;;A61K9/0085;;A61K31/337;;A61K31/4745;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/555,A61K9/00;;A61K9/20;;A61K9/22;;A61K31/282;;A61K31/337;;A61K31/47;;A61K31/4745;;A61K38/00;;A61K39/395;;A61K45/00;;A61K47/34,,0,0,,,,EXPIRED
17,WO,A1,WO 1996/003984 A1,185-064-311-523-151,1996-02-15,1996,US 9509805 W,1995-08-02,US 28434194 A,1994-08-02,CONTROLLED LOCAL DELIVERY OF CHEMOTHERAPEUTIC AGENTS FOR TREATING SOLID TUMORS,"A method and devices for localized delivery of a chemotherapeutic agent to solid tumors, wherein the agent does not cross the blood-brain barrier and is characterized by poor bioavailability and/or short half-lives in vivo, are described. The devices consist of reservoirs which release drug over an extended time period while at the same time preserving the bioactivity and bioavailability of the agent. In the most preferred embodiment, the device consists of biodegradable polymeric matrixes, although reservoirs can also be formulated from non-biodegradable polymers or reservoirs connected to implanted infusion pumps. The devices are implanted within or immediately adjacent the tumors to be treated or the site where they have been surgically removed. The examples demonstrate the efficacy of paclitaxel, camptothecin, and carboplatin delivered in polymeric implants prepared by compression molding of biodegradable and non-biodegradable polymers, respectively. The results are highly statistically significant.",MASSACHUSETTS INST TECHNOLOGY;;UNIV JOHNS HOPKINS;;BREM HENRY;;LANGER ROBERT J;;DOMB ABRAHAM J,BREM HENRY;;LANGER ROBERT J;;DOMB ABRAHAM J,,https://lens.org/185-064-311-523-151,Patent Application,yes,0,34,15,16,0,A61K9/0085;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/337;;A61K31/4745;;A61K31/555;;A61P35/00;;A61K9/0085;;A61K31/337;;A61K31/4745;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/555,A61K9/00;;A61K9/20;;A61K9/22;;A61K31/282;;A61K31/337;;A61K31/47;;A61K31/4745;;A61K38/00;;A61K39/395;;A61K45/00;;A61K47/34,,4,0,,,"CHEMICAL ABSTRACTS, vol. 120, no. 22, 30 May 1994, Columbus, Ohio, US; abstract no. 280088, XP008085312;;CHEMICAL ABSTRACTS, vol. 108, no. 22, 30 May 1988, Columbus, Ohio, US; abstract no. 192636, XP008085311;;CHEMICAL ABSTRACTS, vol. 121, no. 20, 14 November 1994, Columbus, Ohio, US; abstract no. 238234, XP008085310;;CHEMICAL ABSTRACTS, vol. 121, no. 1, 4 July 1994, Columbus, Ohio, US; abstract no. 159, XP008085309",PATENTED
18,CA,A1,CA 2196304 A1,050-077-894-454-801,1996-02-15,1996,CA 2196304 A,1995-08-02,US 28434194 A;;US 9509805 W,1994-08-02,CONTROLLED LOCAL DELIVERY OF CHEMOTHERAPEUTIC AGENTS FOR TREATING SOLID TUMORS,"A method and devices for localized delivery of a chemotherapeutic agent to solid tumors, wherein the agent does not cross the blood-brain barrier and is characterized by poor bioavailability and/or short half-lives in vivo, are described. The devices consist of reservoirs which release drug over an extended time period while at the same time preserving the bioactivity and bioavailability of the agent. In the most preferred embodiment, the device consists of biodegradable polymeric matrixes, although reservoirs can also be formulated from non-biodegradable polymers or reservoirs connected to implanted infusion pumps. The devices are implanted within or immediately adjacent the tumors to be treated or the site where they have been surgically removed. The examples demonstrate the efficacy of paclitaxel, camptothecin, and carboplatin delivered in polymeric implants prepared by compression molding of biodegradable and non-biodegradable polymers, respectively. The results are highly statistically significant.",MASSACHUSETTS INST TECHNOLOGY;;UNIV JOHNS HOPKINS,BREM HENRY;;LANGER ROBERT J;;DOMB ABRAHAM J,,https://lens.org/050-077-894-454-801,Patent Application,no,0,1,15,16,0,A61K9/0085;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/337;;A61K31/4745;;A61K31/555;;A61P35/00;;A61K9/0085;;A61K31/337;;A61K31/4745;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/555,A61K9/00;;A61K9/20;;A61K9/22;;A61K31/282;;A61K31/337;;A61K31/47;;A61K31/4745;;A61K38/00;;A61K39/395;;A61K45/00;;A61K47/34,,0,0,,,,EXPIRED
19,EP,A1,EP 4247941 A1,161-121-429-367-876,2023-09-27,2023,EP 21895591 A,2021-11-18,US 202063115803 P;;US 202163246146 P;;US 2021/0059900 W,2020-11-19,IMMUNO-ONCOLOGY TARGETS TO IMPROVE T-CELL METABOLIC RESPONSE,,UNIV JOHNS HOPKINS,LIM MICHAEL;;JACKSON CHRISTOPHER;;PANT AYUSH;;BREM HENRY,,https://lens.org/161-121-429-367-876,Patent Application,yes,0,0,3,3,0,A61P35/00;;C12N15/1136;;C12N2310/20;;C12N2310/14;;C12N15/1138;;C12N5/0636;;C12N2501/20;;C12N2510/00;;A61K31/7105;;A61K31/713;;A61P37/06;;A61K39/4611;;A61K39/4631;;C07K16/2866;;C12N15/1136;;C12N2310/11;;C12N2310/12;;C12N2310/14;;C12N2310/531,C12N5/0783;;A61K31/7052;;A61K31/7088;;A61P35/00;;C12N15/117,,0,0,,,,PENDING
20,US,A,US 5846565 A,053-069-531-756-367,1998-12-08,1998,US 75073696 A,1996-12-18,US 75073696 A;;US 9509805 W;;US 28434194 A,1994-08-02,Controlled local delivery of chemotherapeutic agents for treating solid tumors,"A method and devices for localized delivery of a chemotherapeutic agent to solid tumors, wherein the agent does not cross the blood-brain barrier and is characterized by poor bioavailability and/or short half-lives in vivo, are described. The devices consist of reservoirs which release drug over an extended period while at the same time preserving the bioactivity and bioavailability of the agent. In the most preferred embodiment, the device consists of biodegradable polymeric matrixes, although reservoirs can also be formulated from non-biodegradable polymers or reservoirs connected to implanted infusion pumps. The devices are implanted within or immediately adjacent the tumors to be treated or the site where they have been surgically removed.",MASSACHUSETTS INST TECHNOLOGY;;UNIV JOHNS HOPKINS,BREM HENRY;;LANGER ROBERT S;;DOMB ABRAHAM J,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1996-12-04);;JOHNS HOPKINS UNIVERSITY THE (1996-12-13),https://lens.org/053-069-531-756-367,Granted Patent,yes,12,96,15,16,0,A61K9/0085;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/337;;A61K31/4745;;A61K31/555;;A61P35/00;;A61K9/0085;;A61K31/337;;A61K31/4745;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/555,A61K9/00;;A61K9/20;;A61K9/22;;A61K31/282;;A61K31/337;;A61K31/47;;A61K31/4745;;A61K38/00;;A61K39/395;;A61K45/00;;A61K47/34,424/486;;424/422;;424/426,0,0,,,,EXPIRED
21,EP,A1,EP 0774964 A1,193-269-045-349-208,1997-05-28,1997,EP 95928721 A,1995-08-02,US 9509805 W;;US 28434194 A,1994-08-02,CONTROLLED LOCAL DELIVERY OF CHEMOTHERAPEUTIC AGENTS FOR TREATING SOLID TUMORS,,MASSACHUSETTS INST TECHNOLOGY;;UNIV JOHNS HOPKINS,BREM HENRY;;LANGER ROBERT J;;DOMB ABRAHAM J,,https://lens.org/193-269-045-349-208,Patent Application,yes,0,0,15,16,0,A61K9/0085;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/337;;A61K31/4745;;A61K31/555;;A61P35/00;;A61K9/0085;;A61K31/337;;A61K31/4745;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/555,A61K9/00;;A61K9/20;;A61K9/22;;A61K31/282;;A61K31/337;;A61K31/47;;A61K31/4745;;A61K38/00;;A61K39/395;;A61K45/00;;A61K47/34,,0,0,,,,EXPIRED
22,EP,B1,EP 0774964 B1,086-484-084-218-027,2005-03-16,2005,EP 95928721 A,1995-08-02,US 9509805 W;;US 28434194 A,1994-08-02,CONTROLLED LOCAL DELIVERY OF CHEMOTHERAPEUTIC AGENTS FOR TREATING SOLID TUMORS,,MASSACHUSETTS INST TECHNOLOGY;;UNIV JOHNS HOPKINS,BREM HENRY;;LANGER ROBERT J;;DOMB ABRAHAM J,,https://lens.org/086-484-084-218-027,Granted Patent,yes,0,0,15,16,0,A61K9/0085;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/337;;A61K31/4745;;A61K31/555;;A61P35/00;;A61K9/0085;;A61K31/337;;A61K31/4745;;A61K9/2027;;A61K9/2031;;A61K9/204;;A61K31/555,A61K9/00;;A61K9/20;;A61K9/22;;A61K31/282;;A61K31/337;;A61K31/47;;A61K31/4745;;A61K38/00;;A61K39/395;;A61K45/00;;A61K47/34,,2,1,069-443-564-555-308,12960135,"Clinical Cancer Research, vol. 9, 3441-3447, 2003;;Martindale 33rd ed., pages 511, 525, 527, 550, 1289, 1842",EXPIRED
23,WO,A3,WO 2016/172494 A3,107-474-222-548-712,2016-12-01,2016,US 2016/0028861 W,2016-04-22,US 201562151619 P,2015-04-23,COMBINATION OF IMMUNOTHERAPY WITH LOCAL CHEMOTHERAPY FOR THE TREATMENT OF MALIGNANCIES,"The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.",UNIV JOHNS HOPKINS,MATHIOS DIMITRIOS;;TYLER BETTY;;PARDOLL DREW;;BREM HENRY;;LIM MICHAEL,,https://lens.org/107-474-222-548-712,Search Report,yes,1,0,7,7,0,C07K16/2818;;A61K2039/505;;A61K39/3955;;A61K45/06;;A61K31/175;;A61P35/00;;A61K31/175;;C07K16/2818;;A61K2039/505,A61K39/395;;A61K9/127;;A61K9/16;;A61P35/00,,4,4,008-826-426-966-294;;074-416-675-238-759;;012-692-090-068-469;;013-779-405-623-155,10.1007/s00262-013-1449-z;;23775421;;11606390;;10811122;;10705027;;10.1016/s0360-3016(99)00464-2,"FRITZELL, S. ET AL.: ""Intratumoral temozolomide synergizes with immunotherapy in a T cell -dependent fashion"", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 62, 2013, pages 1463 - 1474, XP055331842;;TONG, Y. ET AL.: ""Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors"", CANCER RESEARCH, vol. 61, 2001, pages 7530 - 7535, XP055331843;;HURWITZ, A. A. ET AL.: ""Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade"", CANCER RESEARCH, vol. 60, 2000, pages 2444 - 2448, XP009069998;;SERSA, G. ET AL.: ""Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors"", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 46, no. 4, 2000, pages 1037 - 1041, XP055303691",PENDING
24,US,B2,US 11779555 B2,154-158-085-025-009,2023-10-10,2023,US 202017098180 A,2020-11-13,US 202017098180 A;;US 201615136149 A;;US 201562151619 P,2015-04-23,Combination of immunotherapy with local chemotherapy for the treatment of malignancies,"The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.",UNIV JOHNS HOPKINS,MATHIOS DIMITRIOS;;TYLER BETTY;;PARDOLL DREW;;BREM HENRY;;LIM MICHAEL,,https://lens.org/154-158-085-025-009,Granted Patent,yes,5,0,7,7,0,C07K16/2818;;A61K2039/505;;A61K39/3955;;A61K45/06;;A61K31/175;;A61P35/00;;A61K31/175;;C07K16/2818;;A61K2039/505,A61K31/175;;A61K39/00;;C07K16/28,,49,47,074-446-260-677-271;;017-301-757-239-758;;051-446-343-062-817;;038-040-632-602-487;;026-454-211-348-788;;015-213-731-536-495;;089-230-112-444-347;;127-726-591-827-18X;;024-244-836-888-145;;010-033-302-650-53X;;044-128-606-417-88X;;135-071-827-556-394;;003-653-168-575-180;;086-751-695-402-863;;026-180-547-792-932;;002-172-994-727-867;;077-254-000-049-52X;;010-330-081-337-232;;003-016-989-572-604;;045-082-118-149-383;;108-225-105-109-525;;054-984-334-019-515;;025-521-245-155-07X;;045-623-729-340-346;;055-967-742-509-347;;020-266-903-563-917;;048-419-629-020-848;;023-024-890-895-871;;074-076-269-148-127;;125-852-897-442-770;;033-159-791-900-680;;030-058-430-857-689;;105-902-584-695-491;;015-485-848-898-966;;075-583-868-991-266;;005-351-488-315-985;;008-826-426-966-294;;074-416-675-238-759;;012-692-090-068-469;;013-779-405-623-155;;094-690-937-527-735;;108-627-474-398-037;;005-810-500-543-826;;098-600-997-629-833;;066-973-452-502-69X;;076-395-864-120-605;;010-910-457-148-132,10.1093/neuonc/nou212;;pmc4201077;;25190673;;19043418;;10.1038/ni.1679;;pmc2605166;;23613317;;pmc3742575;;10.1158/1078-0432.ccr-12-3314;;10.1056/nejmoa1200694;;pmc3563263;;22658128;;10.1016/0142-9612(90)90030-t;;2090306;;10.1016/s0140-6736(95)90755-6;;7723496;;4345108;;pmc2139329;;10.1084/jem.136.6.1631;;10.2165/00003088-200241060-00002;;12074689;;pmc3162015;;10.1371/journal.pone.0023902;;21901144;;24101040;;pmc3816958;;10.1200/jco.2013.49.6968;;21737504;;10.1158/1078-0432.ccr-11-0774;;pmc3156964;;pmc4111967;;10.1016/j.biocel.2014.04.019;;24796845;;23724846;;pmc4126516;;10.1056/nejmoa1305133;;15705911;;10.1158/0008-5472.1089.65.3;;16775224;;10.1215/15228517-2006-008;;pmc1871955;;10.2217/imt.12.155;;pmc4086484;;23413907;;pmc5217465;;10.1016/j.jconrel.2007.08.003;;17884232;;22761338;;pmc3399042;;10.1158/0008-5472.can-11-3912;;pmc3827073;;10.4161/onci.26294;;24251080;;22877848;;10.1016/s1470-2045(12)70265-6;;18369619;;10.1007/s00262-008-0505-6;;11956096;;23248259;;pmc3538956;;10.4049/jimmunol.1201557;;10.1038/nrc3239;;pmc4856023;;22437870;;10.1007/3-540-30683-8_443;;10.1038/nm1517;;17159987;;16365396;;10.4049/jimmunol.176.1.61;;20921459;;pmc3020702;;10.1200/jco.2010.28.6963;;10.3410/f.6040956.6344054;;21149254;;pmc3064599;;10.1093/neuonc/noq157;;10.1158/1078-0432.ccr-10-1453;;20921209;;pmc2982871;;19269895;;10.1016/s1470-2045(09)70025-7;;22658127;;pmc3544539;;10.1056/nejmoa1200690;;20704886;;pmc3583911;;10.4161/onci.22246;;23482454;;10.1215/s1522851702000236;;10.1093/neuonc/5.2.79;;pmc1920672;;12672279;;10.1215/15228517-5-2-79;;23462419;;pmc3963403;;10.1016/j.ijrobp.2012.12.025;;10.1093/neuonc/nou258.19;;10.1007/s00262-013-1449-z;;23775421;;11606390;;10811122;;10705027;;10.1016/s0360-3016(99)00464-2;;23686484;;10.4049/jimmunol.1203539;;pmc3680135;;24419410;;10.1097/jto.0000000000000074;;19944977;;10.1016/j.nec.2009.09.003;;pmc3269656;;10.1097/ppo.0b013e318244d8ae;;22290262;;25387682;;24904882;;10.14791/btrt.2013.1.1.2;;pmc4027120;;pmc3484478;;10.2147/ce.s23244;;23118709,"Reardon et al., Neuro-Oncology 16(11):1441-58 (Year: 2014).;;Blackburn, S.D., et al., Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral Infection. Nature Immunology. 2009; 10(1): 29-37.;;Bloch, O., et al., Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2013;19(12):3165-75.;;Brahmer, J.R., et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England Journal of Medicine. 2012;366(26):2455-65.;;Brem, H., Polymers to treat brain tumours. Biomaterials. 1990;11(9):699-701.;;Brem, H., et al., Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet. 1995;345(8956):1008-12.;;Brooks, W.H., et al., Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. The Journal of Experimental Medicine. 1972;136(6):1631-47.;;Fleming, A.B. and Saltzman, W.M. Pharmacokinetics of the carmustine implant. Clinical Pharmacokinetics. 2002;41(6):403-19.;;Gabrusiewicz, K., et al., Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PloS One. 2011;6(8):e23902.;;Gilbert, M.R., et al., Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J. Clin. Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(32):4085-91.;;Grossman, S.A., et al., Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2011;17(16):5473-80.;;Hailemichael, Y. and Overwijk, W.W., Cancer vaccines: Trafficking of tumorspecific T cells to tumor after therapeutic vaccination. The International Journal of Biochemistry & Cell Biology. 2014;53:46-50.;;Hamid, O., et al., Safety and tumor responses with lambrolizumab (anti-PD1) in melanoma. The New England Journal of Medicine. 2013;369(2):134-44.;;Hirano et al., Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. Feb. 1, 2005; 65(3): 1089-96.;;Hussain, S.F., et al., The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-Oncology. 2006;8(3):261-79.;;Jackson, C., et al., Vaccine strategies for glioblastoma: progress and future directions. Immunotherapy. 2013;5(2):155-67.;;Kim, G.Y., et al., Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. Journal of Controlled Release : Official Journal of the Controlled Release Society. 2007;123(2):172-8.;;Le, D.T and Jaffee, E.M., Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Research. 2012;72(14):3439-44.;;Litterman, A.J., et al., Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination. Oncoimmunology. 2013;2(10):e26294.;;Malmstrom, A., et al., Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. The Lancet Oncology. 2012;13(9):916-26.;;Menard, C., et al., Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunology, Immunotherapy : CII. 2008;57(11):1579-87.;;Nowak, A.K., et al., Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Research. 2002;62(8):2353-8.;;Ohlfest, J.R., et al., Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. Journal of Immunology. 2013;190(2):613-20.;;Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer. 2012;12(4):252-64.;;Parsa, A.T., et al., Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine 2007;13(1):84-8.;;Preynat-Seauve, O., et al., Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. Journal of Immunology. 2006;176(1):61-7.;;Sampson, J.H., et al., Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology : an Official Journal of the American Society of Clinical Oncology. 2010;28(31):4722-9.;;Smpson, J.H., et al., Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII—expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 2011;13(3):324-33.;;Sarkaria, J.N., et al., Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2010;16(22):5573-80.;;Stupp, R., et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised 25 phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology. 2009;10(5):459-66.;;Topalian, S.L., et al., Safety, activity, and immune correlates of anti-PD1 antibody in cancer. The New England Journal of Medicine. 2012;366(26):2443-54.;;Van Der Most, R.G., et al., Combining immunotherapy with chemotherapy to treat cancer. Discovery Medicine. 2005;5(27):265-70.;;Walter, S., et al., Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901. Oncoimmunology. 2013;2(1):e22246.;;Westphal, M., et al., A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology. 2003;5(2):79-88.;;Zeng, J., et al., Anti-PD1 blockade and stereotactic radiation produce longterm survival in mice with intracranial gliomas. International Journal of Radiation Oncology, Biology, Physics. 2013;86(2):343-9.;;Mathios, IT-21 PD-1 Blockade shows synergistic survival anti tumor immune response and long term memory with interstitial but not systemic chemotherapy: Study in a murine glioblastoma model. Neuro-Oncology. 2014;110(118).;;The International Search Report and the Written Opinion dated Oct. 21, 2016 for a corresponding International Patent Application No. PCT/US2016/028861.;;Fritzell, S. et al., ‘Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion’ Cancer Immunology, Immunotherapy, 2013, vol. 62, pp. 1463-1474 See abstract; and pp. 1465-1467.;;Tong, Y. et al., ‘Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors’ Cancer Research, 2001, vol. 61, pp. 7530-7535 See abstract; and pp. 7531-7533.;;Hurwiiz, A. A. et al., ‘Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade’ Cancer Research, 2000, vol. 60, pp. 2444-2448 See abstract; and pp. 2445-2447.;;Sersa, G. et al., ‘Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors’ International Journal of Radiation Oncology Biology Physics, 2000, vol. 46, No. 4, pp. 1037-1041 See abstract; and pp. 1037-1039.;;Litterman, A. et al., “Profound Impairment of Adaptive Immune Responses by Alkylating Chemotherapy” The Journal of Immunology, May 17, 2013, 190 (12); pp. 6259-6268.;;Champiat et al., “Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC,” Journal of Thoracic Oncology, Feb. 2014, 9(2):144-153.;;Frazier et al., “Immunotherapy Combined with Chemotherapy in the Treatment of Tumors,” Neurosurg Clin N Am, 2010, 21:187-194.;;Zhou et al., “Novel Delivery Strategies for Glioblastoma,” Caner J., 2012, 18(1), (22 pages).;;Kim et al., “Prospects for Targeting PD-1 and PD-L1 in Various Tumor Types,” Cancer Network, <https://www.cancernetwork.com/view/prospects-targeting-pd-1-and-pd-I1-various-tumor-types> dated Nov. 10, 2014 (14 pages).;;Nicholas et al., “Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors,” Brain Tumor Res Treat, 2013, 1:2-8.;;FDA Center for Drug Evaluation and Research, “Summary Review for Application No. 125554Orig1s000,” dated Jul. 30, 2014 (21 pages).;;Kleinberg, “Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide,” Core Evidence, 2012, 7:115-130.",ACTIVE
25,US,A1,US 2023/0414540 A1,055-022-291-297-847,2023-12-28,2023,US 202318460427 A,2023-09-01,US 202318460427 A;;US 202017098180 A;;US 201615136149 A;;US 201562151619 P,2015-04-23,COMBINATION OF IMMUNOTHERAPY WITH LOCAL CHEMOTHERAPY FOR THE TREATMENT OF MALIGNANCIES,"The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.",UNIV JOHNS HOPKINS,MATHIOS DIMITRIOS;;TYLER BETTY;;PARDOLL DREW;;BREM HENRY;;LIM MICHAEL,,https://lens.org/055-022-291-297-847,Patent Application,yes,0,0,7,7,0,C07K16/2818;;A61K2039/505;;A61K39/3955;;A61K45/06;;A61K31/175;;A61P35/00;;A61K31/175;;C07K16/2818;;A61K2039/505,A61K31/175;;C07K16/28,,0,0,,,,PENDING
26,US,B2,US 10864180 B2,176-618-234-863-536,2020-12-15,2020,US 201615136149 A,2016-04-22,US 201615136149 A;;US 201562151619 P,2015-04-23,Combination of immunotherapy with local chemotherapy for the treatment of malignancies,"The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.",UNIV JOHNS HOPKINS,MATHIOS DIMITRIOS;;TYLER BETTY;;PARDOLL DREW;;BREM HENRY;;LIM MICHAEL,THE JOHNS HOPKINS UNIVERSITY (2015-04-24),https://lens.org/176-618-234-863-536,Granted Patent,yes,4,2,7,7,0,C07K16/2818;;A61K2039/505;;A61K39/3955;;A61K45/06;;A61K31/175;;A61P35/00;;A61K31/175;;C07K16/2818;;A61K2039/505,A61K31/175;;A61K39/00;;C07K16/28,,48,44,005-810-500-543-826;;076-395-864-120-605;;098-600-997-629-833;;108-627-474-398-037;;017-301-757-239-758;;051-446-343-062-817;;038-040-632-602-487;;026-454-211-348-788;;015-213-731-536-495;;089-230-112-444-347;;127-726-591-827-18X;;024-244-836-888-145;;010-033-302-650-53X;;044-128-606-417-88X;;135-071-827-556-394;;003-653-168-575-180;;086-751-695-402-863;;026-180-547-792-932;;002-172-994-727-867;;077-254-000-049-52X;;010-330-081-337-232;;003-016-989-572-604;;045-082-118-149-383;;108-225-105-109-525;;054-984-334-019-515;;025-521-245-155-07X;;045-623-729-340-346;;055-967-742-509-347;;020-266-903-563-917;;048-419-629-020-848;;023-024-890-895-871;;074-076-269-148-127;;125-852-897-442-770;;033-159-791-900-680;;030-058-430-857-689;;105-902-584-695-491;;015-485-848-898-966;;075-583-868-991-266;;005-351-488-315-985;;008-826-426-966-294;;074-416-675-238-759;;012-692-090-068-469;;013-779-405-623-155;;094-690-937-527-735,19944977;;10.1016/j.nec.2009.09.003;;24904882;;10.14791/btrt.2013.1.1.2;;pmc4027120;;pmc3269656;;10.1097/ppo.0b013e318244d8ae;;22290262;;24419410;;10.1097/jto.0000000000000074;;19043418;;10.1038/ni.1679;;pmc2605166;;23613317;;pmc3742575;;10.1158/1078-0432.ccr-12-3314;;10.1056/nejmoa1200694;;pmc3563263;;22658128;;10.1016/0142-9612(90)90030-t;;2090306;;10.1016/s0140-6736(95)90755-6;;7723496;;4345108;;pmc2139329;;10.1084/jem.136.6.1631;;10.2165/00003088-200241060-00002;;12074689;;pmc3162015;;10.1371/journal.pone.0023902;;21901144;;24101040;;pmc3816958;;10.1200/jco.2013.49.6968;;21737504;;10.1158/1078-0432.ccr-11-0774;;pmc3156964;;pmc4111967;;10.1016/j.biocel.2014.04.019;;24796845;;23724846;;pmc4126516;;10.1056/nejmoa1305133;;15705911;;10.1158/0008-5472.1089.65.3;;16775224;;10.1215/15228517-2006-008;;pmc1871955;;10.2217/imt.12.155;;pmc4086484;;23413907;;pmc5217465;;10.1016/j.jconrel.2007.08.003;;17884232;;22761338;;pmc3399042;;10.1158/0008-5472.can-11-3912;;pmc3827073;;10.4161/onci.26294;;24251080;;22877848;;10.1016/s1470-2045(12)70265-6;;18369619;;10.1007/s00262-008-0505-6;;11956096;;23248259;;pmc3538956;;10.4049/jimmunol.1201557;;10.1038/nrc3239;;pmc4856023;;22437870;;10.1007/3-540-30683-8_443;;10.1038/nm1517;;17159987;;16365396;;10.4049/jimmunol.176.1.61;;20921459;;pmc3020702;;10.1200/jco.2010.28.6963;;10.3410/f.6040956.6344054;;21149254;;pmc3064599;;10.1093/neuonc/noq157;;10.1158/1078-0432.ccr-10-1453;;20921209;;pmc2982871;;19269895;;10.1016/s1470-2045(09)70025-7;;22658127;;pmc3544539;;10.1056/nejmoa1200690;;20704886;;pmc3583911;;10.4161/onci.22246;;23482454;;10.1215/s1522851702000236;;10.1093/neuonc/5.2.79;;pmc1920672;;12672279;;10.1215/15228517-5-2-79;;23462419;;pmc3963403;;10.1016/j.ijrobp.2012.12.025;;10.1093/neuonc/nou258.19;;10.1007/s00262-013-1449-z;;23775421;;11606390;;10811122;;10705027;;10.1016/s0360-3016(99)00464-2;;23686484;;10.4049/jimmunol.1203539;;pmc3680135,"Frazier et al., Neurosurg Clin N Am, 2010: 21:187-194.;;Nicholas et al., Brain Tumor Res Treat, 2013; 1:2-8.;;Kim & Eder, Cancer Network, Nov. 2014; available at www.cancernetwork.com/oncology-journal/prospects-targeting-pd-1-and-pd-I1-various-tumor-types; last visited Jul. 14, 2017.;;Zhou et al., Cancer J, 2012; 18(1): doi: 10.1097/PPO.0b013e318244d8ae, pp. 1-22.;;L. Kleinberg. Core Evidence 2012:7, doi: 10.2147/CE.S2324 (Year: 2012).;;FDA Center for Drug Research and Evaluation Summary Review for application No. 125554Orig1s000 (Year: 2014).;;Champiat et al., J Thoracic Oncol 9:144-153 (Year: 2014).;;Blackburn, S.D., et al., Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nature Immunology. 2009; 10(1): 29-37.;;Bloch, O., et al., Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2013;19(12):3165-75.;;Brahmer, J.R., et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England Journal of Medicine. 2012;366(26):2455-65.;;Brem, H., Polymers to treat brain tumours. Biomaterials. 1990;11(9):699-701.;;Brem, H., et al., Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet. 1995;345(8956):1008-12.;;Brooks, W.H., et al., Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. The Journal of Experimental Medicine. 1972;136(6):1631-47.;;Fleming, A.B. and Saltzman, W.M. Pharmacokinetics of the carmustine implant. Clinical Pharmacokinetics. 2002;41(6):403-19.;;Gabrusiewicz, K., et al., Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PloS One. 2011;6(8):e23902.;;Gilbert, M.R., et al., Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J. Clin. Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(32):4085-91.;;Grossman, S.A., et al., Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2011;17(16):5473-80.;;Hailemichael, Y. and Overwijk, W.W., Cancer vaccines: Trafficking of tumorspecific T cells to tumor after therapeutic vaccination. The International Journal of Biochemistry & Cell Biology. 2014;53:46-50.;;Hamid, O., et al., Safety and tumor responses with lambrolizumab (anti-PD1) in melanoma. The New England Journal of Medicine. 2013;369(2):134-44.;;Hirano et al., Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. Feb. 1, 2005; 65(3): 1089-96.;;Hussain, S.F., et al., The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-Oncology. 2006;8(3):261-79.;;Jackson, C., et al., Vaccine strategies for glioblastoma: progress and future directions. Immunotherapy. 2013;5(2):155-67.;;Kim, G.Y., et al., Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. Journal of Controlled Release : Official Journal of the Controlled Release Society. 2007;123(2):172-8.;;Le, D.T and Jaffee, E.M., Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Research. 2012;72(14):3439-44.;;Litterman, A.J., et al., Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination. Oncoimmunology. 2013;2(10):e26294.;;Malmstrom, A., et al., Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. The Lancet Oncology. 2012;13(9):916-26.;;Menard, C., et al., Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunology, Immunotherapy : CII. 2008;57(11):1579-87.;;Nowak, A.K., et al., Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Research. 2002;62(8):2353-8.;;Ohlfest, J.R., et al., Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. Journal of Immunology. 2013;190(2):613-20.;;Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer. 2012;12(4):252-64.;;Parsa, A.T., et al., Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine. 2007;13(1):84-8.;;Preynat-Seauve, O., et al., Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. Journal of Immunology. 2006;176(1):61-7.;;Sampson, J.H., et al., Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology : an Official Journal of the American Society of Clinical Oncology. 2010;28(31):4722-9.;;Smpson, J.H., et al., Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 2011;13(3):324-33.;;Sarkaria, J.N., et al., Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2010;16(22):5573-80.;;Stupp, R., et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised 25 phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology. 2009;10(5):459-66.;;Topalian, S.L., et al., Safety, activity, and immune correlates of anti-PD1 antibody in cancer. The New England Journal of Medicine. 2012;366(26):2443-54.;;Van der Most, R.G., et al., Combining immunotherapy with chemotherapy to treat cancer. Discovery Medicine. 2005;5(27):265-70.;;Walter, S., et al., Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901. Oncoimmunology. 2013;2(1):e22246.;;Westphal, M., et al., A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology. 2003;5(2):79-88.;;Zeng, J., et al., Anti-PD1 blockade and stereotactic radiation produce longterm survival in mice with intracranial gliomas. International Journal of Radiation Oncology, Biology, Physics. 2013;86(2):343-9.;;Mathios, IT-21 PD-1 Blockade shows synergistic survival anti tumor immune response and long term memory with interstitial but not systemic chemotherapy: Study in a murine glioblastoma model. Neuro-Oncology. 2014;110(118).;;The International Search Report and the Written Opinion dated Oct. 21, 2016 for a corresponding International Patent Application No. PCT/US2016/028861.;;Fritzell, S. et al., ‘Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion’ Cancer Immunology, Immunotherapy, 2013, vol. 62, pp. 1463-1474 See abstract; and pp. 1465-1467.;;Tong, Y. et al., ‘Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors’ Cancer Research, 2001, vol. 61, pp. 7530-7535 See abstract; and pp. 7531-7533.;;Hurwitz, A. A. et al., ‘Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade’ Cancer Research, 2000, vol. 60, pp. 2444-2448 See abstract; and pp. 2445-2447.;;Sersa, G. et al., ‘Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors’ International Journal of Radiation Oncology Biology Physics, 2000, vol. 46, No. 4, pp. 1037-1041 See abstract; and pp. 1037-1039.;;Litterman, A. et al., “Profound Impairment of Adaptive Immune Responses by Alkylating Chemotherapy” The Journal of Immunology, May 17, 2013, 190 (12); pp. 6259-6268.",ACTIVE
27,US,A1,US 2016/0310453 A1,167-931-213-479-636,2016-10-27,2016,US 201615136149 A,2016-04-22,US 201615136149 A;;US 201562151619 P,2015-04-23,COMBINATION OF IMMUNOTHERAPY WITH LOCAL CHEMOTHERAPY FOR THE TREATMENT OF MALIGNANCIES,"The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.",UNIV JOHNS HOPKINS,MATHIOS DIMITRIOS;;TYLER BETTY;;PARDOLL DREW;;BREM HENRY;;LIM MICHAEL,THE JOHNS HOPKINS UNIVERSITY (2015-04-24),https://lens.org/167-931-213-479-636,Patent Application,yes,1,10,7,7,0,C07K16/2818;;A61K2039/505;;A61K39/3955;;A61K45/06;;A61K31/175;;A61P35/00;;A61K31/175;;C07K16/2818;;A61K2039/505,A61K31/175;;A61K39/395;;C07K16/28,,4,3,005-810-500-543-826;;076-395-864-120-605;;098-600-997-629-833,19944977;;10.1016/j.nec.2009.09.003;;24904882;;10.14791/btrt.2013.1.1.2;;pmc4027120;;pmc3269656;;10.1097/ppo.0b013e318244d8ae;;22290262,"Frazier et al., Neurosurg Clin N Am, 2010: 21:187-194;;Nicholas et al., Brain Tumor Res Treat, 2013; 1:2-8;;Kim & Eder, Cancer Network, November 2014; available at www.cancernetwork.com/oncology-journal/prospects-targeting-pd-1-and-pd-l1-various-tumor-types; last visited 14 July 2017;;Zhou et al., Cancer J, 2012; 18(1): doi: 10.1097/PPO.0b013e318244d8ae, pages 1-22",ACTIVE
28,US,A1,US 2021/0077434 A1,087-766-817-786-497,2021-03-18,2021,US 202017098180 A,2020-11-13,US 202017098180 A;;US 201615136149 A;;US 201562151619 P,2015-04-23,COMBINATION OF IMMUNOTHERAPY WITH LOCAL CHEMOTHERAPY FOR THE TREATMENT OF MALIGNANCIES,"The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.",UNIV JOHNS HOPKINS,MATHIOS DIMITRIOS;;TYLER BETTY;;PARDOLL DREW;;BREM HENRY;;LIM MICHAEL,,https://lens.org/087-766-817-786-497,Patent Application,yes,1,0,7,7,0,C07K16/2818;;A61K2039/505;;A61K39/3955;;A61K45/06;;A61K31/175;;A61P35/00;;A61K31/175;;C07K16/2818;;A61K2039/505,A61K31/175;;C07K16/28,,1,1,074-446-260-677-271,10.1093/neuonc/nou212;;pmc4201077;;25190673,"Reardon et al., Neuro-Oncology 16(11):1441-58 (Year: 2014)",ACTIVE
29,WO,A2,WO 2016/172494 A2,167-163-464-662-807,2016-10-27,2016,US 2016/0028861 W,2016-04-22,US 201562151619 P,2015-04-23,COMBINATION OF IMMUNOTHERAPY WITH LOCAL CHEMOTHERAPY FOR THE TREATMENT OF MALIGNANCIES,"The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.",UNIV JOHNS HOPKINS,MATHIOS DIMITRIOS;;TYLER BETTY;;PARDOLL DREW;;BREM HENRY;;LIM MICHAEL,,https://lens.org/167-163-464-662-807,Patent Application,yes,0,2,7,7,0,C07K16/2818;;A61K2039/505;;A61K39/3955;;A61K45/06;;A61K31/175;;A61P35/00;;A61K31/175;;C07K16/2818;;A61K2039/505,A61K9/127;;A61K39/395;;A61K9/16;;A61P35/00,,0,0,,,,PENDING
30,WO,A1,WO 2016/025786 A1,026-587-962-287-364,2016-02-18,2016,US 2015/0045194 W,2015-08-14,US 201462037981 P,2014-08-15,POST-SURGICAL IMAGING MARKER,A marker for imaging includes a bio-dissolvable material and a contrast agent configured to provide contrast during an imaging procedure. A method can include forming a marker for imaging from a bio-dissolvable material and impregnating the bio-dissolvable material with a contrast agent. A method can include implanting a bio-dissolvable marker for imaging into a patient.,UNIV JOHNS HOPKINS,LIM MICHAEL;;BREM HENRY;;TYLER BETTY;;LIAUW JASON;;LO SHENG-FU,,https://lens.org/026-587-962-287-364,Patent Application,yes,4,0,3,3,0,A61K49/101;;A61K49/1803;;A61K49/1827;;A61K49/101;;A61K49/1803;;A61K49/1827;;A61K49/12;;A61K49/1896,A61K49/06;;A61K49/04;;A61K49/10;;A61K51/02,,1,1,018-592-826-304-197,pmc2556256;;10.1200/jco.2006.06.6290;;17264335,"WEINGART, J. ET AL.: ""Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous 06-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial"", JOURNAL OF CLINICAL ONCOLOGY, vol. 25, no. 4, 2007, pages 399 - 404",PENDING
31,US,B2,US 10195190 B2,170-506-664-740-654,2019-02-05,2019,US 201615549547 A,2016-02-11,US 201615549547 A;;US 201562114652 P;;US 2016/0017493 W,2015-02-11,Local delivery forms of acriflavine for treating tumors,"Local delivery formulations of the antineoplastic and microbicide agent acriflavine, and methods of making and using thereof are significantly more efficacious at increasing the median survival of subjects with proliferative disease than systemic administrations of acriflavine. The local delivery formulations of acriflavine show a dose-dependent increase in the median survival of subjects. The local delivery forms provide the increased efficacy without the toxicity associated with systemic administration of the agent.",UNIV JOHNS HOPKINS,BREM HENRY;;MANGRAVITI ANTONELLA;;OLIVI ALESSANDRO;;TYLER BETTY M;;RAGHAVAN TULA,THE JOHNS HOPKINS UNIVERSITY (2016-03-03),https://lens.org/170-506-664-740-654,Granted Patent,yes,11,0,5,5,0,A61K31/473;;A61K31/473;;A61K9/0024;;A61K9/0024;;A61K31/4188;;A61K31/4188;;A61K47/34;;A61K47/34;;A61P35/00,A61K31/473;;A61K9/00;;A61K31/4188;;A61K47/34,,26,24,048-003-040-152-582;;043-183-245-857-913;;063-850-777-436-505;;127-049-799-980-313;;030-044-346-363-398;;019-264-483-343-031;;000-780-602-509-323;;008-715-898-141-993;;007-264-609-214-994;;024-528-404-626-824;;033-307-081-163-315;;077-254-000-049-52X;;089-692-123-088-153;;034-930-623-115-168;;049-898-241-363-702;;050-602-961-304-153;;030-403-608-378-058;;112-454-797-947-768;;013-773-613-930-646;;045-246-035-209-692;;055-042-922-753-043;;042-423-164-191-412;;025-239-605-617-524;;076-791-646-975-976,10.18632/oncoscience.109;;25621294;;pmc4303887;;446779;;10.1016/s0015-0282(16)44002-1;;6527243;;10.1002/jps.2600731215;;10.1073/pnas.0907357106;;pmc2726037;;19706526;;10.1007/s00289-014-1230-2;;12667889;;10.1016/s0163-7258(03)00014-7;;15687310;;10.1001/jama.293.5.557;;10.1007/s13277-014-2156-x;;24961347;;22911853;;10.1371/journal.pone.0041760;;pmc3404071;;10.1111/j.1349-7006.2011.02097.x;;21910782;;10.3171/jns.1995.82.3.0481;;7861228;;pmc5217465;;10.1016/j.jconrel.2007.08.003;;17884232;;9443855;;19805192;;10.1073/pnas.0909353106;;pmc2764905;;24982368;;10.3171/2013.11.focus13486;;24484254;;2205908;;10.1016/0167-6989(87)90098-5;;10.1038/nrc2607;;19377506;;pmc2748742;;10.1039/c4ra06475e;;10.1517/14712598.5.4.477;;15934827;;10.1227/01.neu.0000365263.14725.39;;20173548;;9054951;;10.1007/s002800050588;;10.1038/nmat1005;;14593392,"Alfarouk, et al, “Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question”, Oncoscience 1(14):777-802 (2014).;;Beck et al., “A New Long-Acting Injectable Microcapsule System for the Administration of Progesterone,” Fertil. Steril., 31:545-51 (1979).;;Benita, et al., “Characterization of Drug-Loaded Poly( d,Z-lactide) Microspheres”J. Pharm. Sci., 73:1721-4 (1984).;;Bertout, et al., “HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses”, PNAS, 106:14391-6 (2009).;;Can and Kaplan, “Synthesis, characterization and in vitro antibacterial assessments of a novel modified poly[maleic anhydride-alt-a-acrylic acid]/acriflavine conjugate”, Polymer Bulletin, 71(11):2903-21 (2014).;;Castro, et al., “Current and future strategies for the treatment of malignant brain tumors”, Pharmacol. Ther. 98(1):71-108 (2003).;;Chang, et al., “Patterns of care for adults with newly diagnosed malignant glioma”, JAMA, 293(20):557-64 (2005).;;Fan, et al., “Acriflavine suppresses the growth of human osteosarcoma cells through apoptosis and autophagy”, Tumour Biol., 35(10):9571-6 (2014).;;Foersch, et al., “Confocal Laser Endomicroscopy for Dagnosis and Histomorphologic Imaging of Brain Tumors In Vivo”, PLoS. ONE, 7(7):e41760 (2012).;;Hassan, et, al., “Novel activity of acriflavine against colorectal cancer tumor cells” Cancer Sci., 102(12):2206-13 (2011).;;Judy, et al., “Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas.” J Neurosurg. 82:481-6 (1995).;;Kim, et al., “Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model”, J Control Release., 123(2):172-8 (2007).;;Kim, et al., “Suppression of xenobiotic-metabolizing enzyme expression in rats by acriflavine, a protein kinase C inhibitor. Effects on epoxide hydrolase, glutathione S-transferases, and cytochromes p450”, Drug Metab Dispos., 28(1):66-72 (1998).;;Lee, et al., “Acriflavine inhibits HIF-1 dimerization, tumor growth and vascularization” PNAS, 106 (42):17910-5(2009).;;Lee, et al., “Antitumor activity of acriflavine in human hepatocellular carcinoma cells”, Anticancer Res., 34(7):3549-56 (2014).;;Macia, et al., “Antianglogenic therapy in the squamous cell carcinoma”, Intl J Oral Maxillofacial Surg., 42(10):1173-4 (2013).;;Martirosyan, et al., “Potential application of a handheld confocal endomicroscope imaging system using a variety of fluorophores in experimental gliomas and normal brain”, Neurosurg Focus, 36 (2):E16, (2014).;;Mathiowitz et al., “Morphology of polyanhydride microsphere delivery systems,” J. Scanning Microscopy, 4:329-40 (1990).;;Mathiowitz, et al., “Novel microcapsules for delively systems” Reactive Polymers, 6:275-83 (1987).;;Nitiss, “Targeting DNA topolsomerase II in cancer chemotherapy”, Nat Rev Cancer, 9(5): 338-50 (2009).;;Palvai, et al., “Dual drug loaded vitamin D3 nanoparticle to target drug resistance in cancer”, RSC Adv., 4(100):57271-81 (2014).;;Raza, et al. “Local delivery of antineoplasti agents by controlled-release polymers for the treatment of malignant brain tumours”, Expert Opin. Biol. Ther. 5(4):477-494 (2005).;;Recinos, et al., “Combination orf Intracranial Temozolomide With Intracranial Carmustine Improves Survival When Compared With Either Treatment Alone in a Rodent Glioma Model”, Neurosurgery, 6:530-7 (2010).;;Sipos, et al., “Optimising interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors”, Cancer Chemother Pharmacol., 39(5):383-9 (1997).;;West et al., “Drug delivery: Pulsed polymers” Nat Mater., 2(11):709-10 (2003).;;International Search Report for corresponding PCT application PCT/US2016/017493 dated Aug. 24, 2017.",ACTIVE
32,WO,A1,WO 2016/130767 A1,053-579-379-029-789,2016-08-18,2016,US 2016/0017493 W,2016-02-11,US 201562114652 P,2015-02-11,LOCAL DELIVERY FORMS OF ACRIFLAVINE FOR TREATING TUMORS,"Local delivery formulations of the antineoplastic and microbicide agent acriflavine, and methods of making and using thereof are significantly more efficacious at increasing the median survival of subjects with proliferative disease than systemic administrations of acriflavine. The local delivery formulations of acriflavine show a dose-dependent increase in the median survival of subjects. The local delivery forms provide the increased efficacy without the toxicity associated with systemic administration of the agent.",UNIV JOHNS HOPKINS,BREM HENRY;;MANGRAVITI ANTONELLA;;OLIVI ALESSANDRO;;TYLER BETTY M;;RAGHAVAN TULA,,https://lens.org/053-579-379-029-789,Patent Application,yes,10,0,5,5,0,A61K9/0024;;A61K47/34;;A61K31/473;;A61K31/4188;;A61P35/00;;A61K9/0024;;A61K47/34;;A61K31/473;;A61K31/4188,A61K31/473;;A61K9/00;;A61K47/34;;A61P35/00,,27,23,020-870-186-053-711;;045-246-035-209-692;;025-239-605-617-524;;030-044-346-363-398;;034-930-623-115-168;;008-715-898-141-993;;024-528-404-626-824;;049-898-241-363-702;;048-003-040-152-582;;127-049-799-980-313;;013-773-613-930-646;;089-692-123-088-153;;050-602-961-304-153;;007-264-609-214-994;;030-403-608-378-058;;043-183-245-857-913;;063-850-777-436-505;;077-254-000-049-52X;;000-780-602-509-323;;055-042-922-753-043;;019-264-483-343-031;;025-239-605-617-524;;042-423-164-191-412,10.1016/j.ijom.2013.07.024;;10.1039/c4ra06475e;;9054951;;10.1007/s002800050588;;10.1007/s00289-014-1230-2;;19805192;;10.1073/pnas.0909353106;;pmc2764905;;10.1007/s13277-014-2156-x;;24961347;;10.1111/j.1349-7006.2011.02097.x;;21910782;;24982368;;10.18632/oncoscience.109;;25621294;;pmc4303887;;10.1073/pnas.0907357106;;pmc2726037;;19706526;;10.1038/nrc2607;;19377506;;pmc2748742;;9443855;;10.3171/2013.11.focus13486;;24484254;;22911853;;10.1371/journal.pone.0041760;;pmc3404071;;2205908;;446779;;10.1016/s0015-0282(16)44002-1;;6527243;;10.1002/jps.2600731215;;pmc5217465;;10.1016/j.jconrel.2007.08.003;;17884232;;15687310;;10.1001/jama.293.5.557;;10.1517/14712598.5.4.477;;15934827;;12667889;;10.1016/s0163-7258(03)00014-7;;9054951;;10.1007/s002800050588;;10.1227/01.neu.0000365263.14725.39;;20173548,"MACIA G ET AL: ""Antiangiogenic therapy in the squamous cell carcinoma"", INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, vol. 42, no. 10, October 2013 (2013-10-01), pages 1173 - 1174, XP028751324, ISSN: 0901-5027, DOI: 10.1016/J.IJOM.2013.07.024;;SANDEEP PALVAI ET AL: ""Dual drug loaded vitamin D3 nanoparticle to target drug resistance in cancer"", RSC ADV., vol. 4, no. 100, January 2014 (2014-01-01), pages 57271 - 57281, XP055264775, DOI: 10.1039/C4RA06475E;;ERIC P SIPOS ET AL: ""OR IGINAL A RTI CLE Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors"", CANCER CHEMOTHER PHARMACOL, January 1997 (1997-01-01), pages 383 - 389, XP055264782, Retrieved from the Internet <URL:http://rd.springer.com/content/pdf/10.1007/s002800050588.pdf>;;CAN HATICE KAPLAN ET AL: ""Synthesis, characterization and in vitro antibacterial assessments of a novel modified poly[maleic anhydride-alt-acrylic acid]/acriflavine conjugate"", POLYMER BULLETIN, SPRINGER, HEIDELBERG, DE, vol. 71, no. 11, 3 September 2014 (2014-09-03), pages 2903 - 2921, XP035407281, ISSN: 0170-0839, [retrieved on 20140903], DOI: 10.1007/S00289-014-1230-2;;LEE ET AL., PROC NATL ACAD SCI USA, vol. 106, no. 42, 2009, pages 17910 - 7915;;FAN ET AL., TUMOUR BIOL, vol. 35, no. 10, 2014, pages 9571 - 9576;;HASSAN ET AL., CANCER SCIENCE, vol. 102, no. 12, 2011, pages 2206 - 213;;LEE ET AL., ANTICANCER RES., vol. 34, no. 7, 2014, pages 3549 - 3556;;ALFAROUK ET AL., ONCOSCIENCE, vol. 1, no. 14, 2014, pages 777 - 802;;BERTOUT ET AL., PROC NATL ACAD SCI USA, vol. 106, 2009, pages 14391 - 14396;;NITISS, NATURE REVIEWS CANCER, vol. 9, no. 5, 2009, pages 338 - 350;;KIM ET AL., DRUG METABOLISM AND DISPOSITION, vol. 26, no. 1, 1998, pages 66 - 72;;MARTIROSYAN ET AL., NEUROSURG FOCUS, vol. 36, no. 2, 2014, pages E16;;FOERSCH ET AL., PLOS ONE, vol. 7, no. 7, 2012, pages E41760;;E. MATHIOWITZ, J. SCANNING MICROSCOPY, vol. 4, 1990, pages 329;;L. R. BECK ET AL., FERTIL. STERIL., vol. 31, 1979, pages 545;;S. BENITA, J. PHARM. SCI., vol. 73, 1984, pages 1721;;MATHIOWITZ, REACTIVE POLYMERS, vol. 6, 1987, pages 275;;RICHARDS ET AL., NAT MATER., vol. 2, no. 11, 2003, pages 709 - 10;;KIM ET AL., J CONTROL RELEASE., vol. 123, no. 2, 2007, pages 172 - 8;;CHANG, JAMA, vol. 293, no. 20, 2005, pages 557 - 564;;RAZA ET AL., EXPERT OPIN. BIOL. THER., vol. 5, no. 4, 2005, pages 477 - 494;;CASTRO ET AL., PHARMACOL. THER., vol. 98, no. 1, 2003, pages 71 - 108;;SIPOS ET AL., CANCER CHEMOTHERAPY & PHARMACOLOGY, vol. 39, no. 5, 1997, pages 383 - 389;;CHASIN ET AL., BIOPHARM MANUFACT, vol. 1, 1988, pages 33;;JUDY ET AL., J NEUROSURG, vol. 82, 1995, pages 103;;RECINOS ET AL., NEUROSURGERY, vol. 66, 2010, pages 530 - 537",PENDING
33,US,B2,US 11191853 B2,093-928-172-510-907,2021-12-07,2021,US 201515503887 A,2015-08-14,US 201515503887 A;;US 201462037981 P;;US 2015/0045194 W,2014-08-15,Post-surgical imaging marker,A marker for imaging includes a bio-dissolvable material and a contrast agent configured to provide contrast during an imaging procedure. A method can include forming a marker for imaging from a bio-dissolvable material and impregnating the bio-dissolvable material with a contrast agent. A method can include implanting a bio-dissolvable marker for imaging into a patient.,UNIV JOHNS HOPKINS,LIM MICHAEL;;BREM HENRY;;TYLER BETTY;;LIAUW JASON;;LO SHENG-FU,THE JOHNS HOPKINS UNIVERSITY (2017-03-28),https://lens.org/093-928-172-510-907,Granted Patent,yes,27,0,3,3,0,A61K49/101;;A61K49/1803;;A61K49/1827;;A61K49/101;;A61K49/1803;;A61K49/1827;;A61K49/12;;A61K49/1896,A61K49/18;;A61K49/10;;A61K49/12,,4,2,018-592-826-304-197;;018-592-826-304-197,pmc2556256;;10.1200/jco.2006.06.6290;;17264335;;pmc2556256;;10.1200/jco.2006.06.6290;;17264335,"Weingart, J. et al., Phase I trial of polifeprosan 20 with carmustine 3 implant plus continuous infusion of intravenous 06-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial, Journal of Clinical Oncology, 2007, vol. 25, No. 4, pp. 399-404.;;Weingart, J., et al., Phase 1 trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous 06-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial, Journal of Clinical Oncology, 2007, vol. 25, No. 4, pp. 399-404.;;International Search Report issued in corresponding International Application No. PCT/US2015/045194, dated Oct. 29, 2015, 4 pages.;;Written Opinion of the International Searching Authority issued in corresponding International Application No. PCT/US2015/045194, dated Oct. 29, 2015, 7 pages.",ACTIVE
34,US,A1,US 2017/0274102 A1,046-747-984-702-405,2017-09-28,2017,US 201515503887 A,2015-08-14,US 201515503887 A;;US 201462037981 P;;US 2015/0045194 W,2014-08-15,POST-SURGICAL IMAGING MARKER,A marker for imaging includes a bio-dissolvable material and a contrast agent configured to provide contrast during an imaging procedure. A method can include forming a marker for imaging from a bio-dissolvable material and impregnating the bio-dissolvable material with a contrast agent. A method can include implanting a bio-dissolvable marker for imaging into a patient.,UNIV JOHNS HOPKINS,LIM MICHAEL;;BREM HENRY;;TYLER BETTY;;LIAUW JASON;;LO SHENG-FU,THE JOHNS HOPKINS UNIVERSITY (2017-03-28),https://lens.org/046-747-984-702-405,Patent Application,yes,10,2,3,3,0,A61K49/101;;A61K49/1803;;A61K49/1827;;A61K49/101;;A61K49/1803;;A61K49/1827;;A61K49/12;;A61K49/1896,A61K49/18;;A61K49/10;;A61K49/12,,0,0,,,,ACTIVE
35,EP,A1,EP 3256129 A1,013-833-611-354-923,2017-12-20,2017,EP 16706120 A,2016-02-11,US 201562114652 P;;US 2016/0017493 W,2015-02-11,LOCAL DELIVERY FORMS OF ACRIFLAVINE FOR TREATING TUMORS,,UNIV JOHNS HOPKINS,BREM HENRY;;MANGRAVITI ANTONELLA;;OLIVI ALESSANDRO;;TYLER BETTY M;;RAGHAVAN TULA,,https://lens.org/013-833-611-354-923,Patent Application,yes,0,0,5,5,0,A61K9/0024;;A61K47/34;;A61K31/473;;A61K31/4188;;A61P35/00;;A61K9/0024;;A61K47/34;;A61K31/473;;A61K31/4188,A61K31/473;;A61K9/00;;A61K47/34;;A61P35/00,,0,0,,,,PENDING
36,US,A1,US 2018/0036301 A1,098-956-053-848-171,2018-02-08,2018,US 201615549547 A,2016-02-11,US 201615549547 A;;US 201562114652 P;;US 2016/0017493 W,2015-02-11,LOCAL DELIVERY FORMS OF ACRIFLAVINE FOR TREATING TUMORS,"Local delivery formulations of the antineoplastic and microbicide agent acriflavine, and methods of making and using thereof are significantly more efficacious at increasing the median survival of subjects with proliferative disease than systemic administrations of acriflavine. The local delivery formulations of acriflavine show a dose-dependent increase in the median survival of subjects. The local delivery forms provide the increased efficacy without the toxicity associated with systemic administration of the agent.",UNIV JOHNS HOPKINS,BREM HENRY;;MANGRAVITI ANTONELLA;;OLIVI ALESSANDRO;;TYLER BETTY M;;RAGHAVAN TULA,THE JOHNS HOPKINS UNIVERSITY (2016-03-03),https://lens.org/098-956-053-848-171,Patent Application,yes,0,0,5,5,0,A61K31/473;;A61K31/473;;A61K9/0024;;A61K9/0024;;A61K31/4188;;A61K31/4188;;A61K47/34;;A61K47/34;;A61P35/00,A61K31/473;;A61K9/00;;A61K31/4188,,0,0,,,,ACTIVE
37,WO,A1,WO 2018/160657 A1,150-191-776-064-073,2018-09-07,2018,US 2018/0020159 W,2018-02-28,US 201762464511 P,2017-02-28,FLEXIBLE CONTROL AND GUIDANCE OF MINIMALLY INVASIVE FOCUSED ULTRASOUND,"An embodiment in accordance with the present invention provides a transducer design for minimally invasive focused ultrasound (MIFU). The present invention allows flexible control of a focused ultrasound wave using mechanical and electrical control. The transducer array is implemented on a flexible substrate that can be mechanically controlled through two or more physical configurations. As with conventional electronic ""steering,"" the transducer elements can be controlled electronically to provide adjustable focus of the ultrasound. The combination of mechanical and electronic control provides the device a very flexible method for delivering focused ultrasound. The invention also includes a design that allows integration of ultrasound and endoscopic image guidance. The ultrasound guidance includes anatomical visualization and functional imaging (e.g. blood flow and coagulation of vasculature). The ultrasound imaging transducer is used for thermometry within the region of interest for treatment. Endoscopic imaging allows for improved understanding of tip location in real-time.",UNIV JOHNS HOPKINS,MANBACHI AMIR;;SIEWERDSEN JEFFREY;;ELLENS NICHOLAS;;ZHENG XIAOXUAN;;BELZBERG MICAH;;COHEN ALAN;;BREM HENRY,,https://lens.org/150-191-776-064-073,Patent Application,yes,5,0,2,2,0,A61B8/12;;A61N7/02;;A61B8/00;;A61B8/06;;A61B8/0841;;A61B8/0841;;A61B8/085;;A61B8/085;;A61B8/12;;A61B8/485;;A61B34/20;;A61N7/02;;A61N2007/0004;;A61N2007/0078;;A61N2007/0078;;A61N2007/0086;;A61N2007/0095,A61B8/00;;A61N7/02,,0,0,,,,PENDING
38,US,A1,US 2020/0001121 A1,041-239-825-148-758,2020-01-02,2020,US 201816489423 A,2018-02-28,US 201816489423 A;;US 201762464511 P;;US 2018/0020159 W,2017-02-28,FLEXIBLE CONTROL AND GUIDANCE OF MINIMALLY INVASIVE FOCUSED ULTRASOUND,"An embodiment in accordance with the present invention provides a transducer design for minimally invasive focused ultrasound (MIFU). The present invention allows flexible control of a focused ultrasound wave using mechanical and electrical control. The transducer array is implemented on a flexible substrate that can be mechanically controlled through two or more physical configurations. As with conventional electronic “steering,” the transducer elements can be controlled electronically to provide adjustable focus of the ultrasound. The combination of mechanical and electronic control provides the device a very flexible method for delivering focused ultrasound. The invention also includes a design that allows integration of ultrasound and endoscopic image guidance. The ultrasound guidance includes anatomical visualization and functional imaging (e.g. blood flow and coagulation of vasculature). The ultrasound imaging transducer is used for thermometry within the region of interest for treatment. Endoscopic imaging allows for improved understanding of tip location in real-time.",UNIV JOHNS HOPKINS,MANBACHI AMIR;;SIEWERDSEN JEFFREY;;ELLENS NICHOLAS;;ZHENG XIAOXUAN;;BELZBERG MICAH;;COHEN ALAN;;BREM HENRY,THE JOHNS HOPKINS UNIVERSITY (2020-03-31),https://lens.org/041-239-825-148-758,Patent Application,yes,7,1,2,2,0,A61B8/00;;A61B8/06;;A61B8/0841;;A61B8/085;;A61B8/12;;A61N7/02;;A61B8/485;;A61N2007/0078;;A61N2007/0095;;A61B34/20;;A61B8/0841;;A61B8/085;;A61N7/02;;A61N2007/0004;;A61N2007/0078;;A61N2007/0086;;A61B8/12,A61N7/02;;A61B8/08,,3,3,024-860-166-646-700;;100-742-575-513-287;;075-799-822-385-546,20087132;;pmc2939497;;10.1227/01.neu.0000360379.95800.2f;;pmc5558564;;10.7150/thno.19662;;28819458;;10.1118/1.4892923;;25186419,"McDannold N, Clement GT, Black P, Jolesz F, Hynynen K. Transcranial magnetic resonance imaging- guided focused ultrasound surgery of brain tumors: initial findings in 3 patients. Neurosurgery. 2010 Feb;66(2):323-32; discussion 332. doi: 10.1227/01.NEU.0000360379.95800.2F. (Year: 2010);;Santos MA, Goertz DE, Hynynen K. Focused Ultrasound Hyperthermia Mediated Drug Delivery Using Thermosensitive Liposomes and Visualized With in vivo Two-Photon Microscopy. Theranostics 2017; 7(10):2718-2731. doi:10.7150/thno.19662. https://www.thno.org/v07p2718.htm (Year: 2017);;N'Djin WA, Burtnyk M, Lipsman N, Bronskill M, Kucharczyk W, Schwartz ML, Chopra R. Active MR-temperature feedback control of dynamic interstitial ultrasound therapy in brain: in vivo experiments and modeling in native and coagulated tissues. Med Phys. 2014 Sep;41(9):093301. (Year: 2014)",PENDING
39,WO,A1,WO 2023/158834 A1,037-099-908-034-215,2023-08-24,2023,US 2023/0013362 W,2023-02-17,US 202263311926 P,2022-02-18,SYSTEMS AND METHODS FOR DETECTION AND LOCALIZATION OF FOREIGN BODY OBJECTS,"Systems and methods for detection and localization of a foreign body object in a region are provided. In embodiments, a system can a processor and one or more computer- readable storage media storing instructions which, when executed on the processor, cause the processor to perform a method for forming a trained model using a plurality of training images and a plurality of training boundary data sets. The systems and methods further apply the trained model to process an image and generate a boundary data set. In embodiments, the image can be an ultrasound image, and the boundary data set can correspond to a bounding box enclosing the foreign body object.",UNIV JOHNS HOPKINS,MANBACHI AMIR;;ABRAMSON HALEY GILBERT;;HUANG JUDY;;BREM HENRY;;THEODORE NICHOLAS;;COLES GEORGE L,,https://lens.org/037-099-908-034-215,Patent Application,yes,6,0,1,1,0,G16H50/70;;G16H50/20;;G16H30/40;;G16H20/40;;G06N3/0464;;G06N3/09;;G06N3/082;;G06N3/048;;A61B8/5223;;A61B8/5207;;A61B8/461;;A61B8/468;;A61B8/469,G06T7/11;;G06N3/02;;G16H30/00,,1,0,,,"YANG XU; YIHENG XU; TENGCHAO LV; LEI CUI; FURU WEI; GUOXIN WANG; YIJUAN LU; DINEI FLORENCIO; CHA ZHANG; WANXIANG CHE; MIN ZHANG; L: ""LayoutLMv2: Multi-modal Pre-training for Visually-Rich Document Understanding"", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 10 January 2022 (2022-01-10), 201 Olin Library Cornell University Ithaca, NY 14853, XP091125032",PENDING
40,CA,A1,CA 2267977 A1,137-917-020-580-886,1998-04-23,1998,CA 2267977 A,1997-10-15,US 73159796 A;;US 9718455 W,1996-10-16,CYTOKINE ENHANCED IMMUNOTHERAPY FOR BRAIN TUMORS,"A therapy for treatment of patients with cancer utilizing the combination of a cytokine in a pharmaceutically acceptable carrier for systemic administration and a cytokine in a pharmaceutically acceptable carrier for local administration is described. In the most preferred embodiment, brain tumors are treated with a cytokine such as GM-CSF administered systemically, most preferably in combination with tumor antigen such as replication incompetent tumor cells, and a cytokine such as IL-2 or IL-4 administered locally, most preferably in a vehicle providing release over a period of time, such as transduced cells, again most preferably replication incompetent tumor cells, or incorporated into microparticulate vehicles such as polymeric microspheres.",UNIV JOHNS HOPKINS,EWEND MATTHEW G;;BREM HENRY;;THOMPSON REID C;;PARDOLL DREW M;;JAFFEE ELIZABETH M;;LEONG KAM W,,https://lens.org/137-917-020-580-886,Patent Application,no,0,0,5,5,0,A61K9/0085;;A61K39/0011;;A61K48/00;;A61P35/00;;A61K39/0011,A61K9/50;;A61K9/00;;A61K35/12;;A61K38/00;;A61K39/00;;A61K47/30;;A61K48/00;;A61P35/00,,0,0,,,,DISCONTINUED
41,WO,A1,WO 1998/016246 A1,171-824-589-278-331,1998-04-23,1998,US 9718455 W,1997-10-15,US 73159796 A,1996-10-16,CYTOKINE ENHANCED IMMUNOTHERAPY FOR BRAIN TUMORS,"A therapy for treatment of patients with cancer utilizing the combination of a cytokine in a pharmaceutically acceptable carrier for systemic administration and a cytokine in a pharmaceutically acceptable carrier for local administration is described. In the most preferred embodiment, brain tumors are treated with a cytokine such as GM-CSF administered systemically, most preferably in combination with tumor antigen such as replication incompetent tumor cells, and a cytokine such as IL-2 or IL-4 administered locally, most preferably in a vehicle providing release over a period of time, such as transduced cells, again most preferably replication incompetent tumor cells, or incorporated into microparticulate vehicles such as polymeric microspheres.",UNIV JOHNS HOPKINS;;BREM HENRY;;PARDOLL DREW M;;THOMPSON REID C;;JAFFEE ELIZABETH M;;LEONG KAM W;;EWEND MATTHEW G,BREM HENRY;;PARDOLL DREW M;;THOMPSON REID C;;JAFFEE ELIZABETH M;;LEONG KAM W;;EWEND MATTHEW G,,https://lens.org/171-824-589-278-331,Patent Application,yes,0,16,5,5,0,A61K9/0085;;A61K39/0011;;A61K48/00;;A61P35/00;;A61K39/0011,A61K9/00;;A61K35/12;;A61K9/50;;A61K38/00;;A61K39/00;;A61K47/30;;A61K48/00;;A61P35/00,,8,8,051-030-157-212-288;;024-188-635-849-779;;051-613-770-841-781;;017-145-308-581-003;;035-428-926-783-801;;087-879-787-031-413;;031-656-787-332-056;;063-314-702-366-54X,7621236;;10.1006/jsre.1995.1034;;7861776;;8564954;;10.1038/bjc.1996.308;;pmc2074618;;8679459;;8423625;;10.1093/jnci/85.3.207;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;8261390;;9041459;;10.1097/00002371-199611000-00004,"PIPPIN ET AL: ""LOCAL IL-4 DELIVERY ENHANCES IMMUNE REACTIVITY TO MURINE TUMORS: GENE THERAPY IN COMBINATION WITH IL2"", CANCER GENE THERAPY, vol. 1, no. 1, 1994, pages 35 - 42, XP002057835;;PAPPO ET AL: ""ADMINISTRATION OF SYSTEMIC OR LOCAL INTERLEUKIN-2 ENHANCES THE ANTI-TUMOR EFFECTS OF INTERLEUKIN-12 GENE THERAPY"", JOURNAL OF SURGICAL RESEARCH, vol. 58, 1995, pages 218 - 226, XP002057836;;VAGLIANI ET AL: ""INTERLEUKIN 12 POTENTIATES THE CURATIVE EFFECT OF A VACCINE BASED ON INTERLEUKIN 2-TRANSDUCED TUMOR CELLS"", CANCER RESEARCH, vol. 56, 1 February 1996 (1996-02-01), pages 467 - 470, XP002057837;;HOLLINGSWORTH ET AL: ""THE EFFECT OF COMBINED EXPRESSSION OF INTERLEUKIN 2 AND INTERLEUKIN 4 ON THE TUMORIGENICITY AND TREATMENT OF B16F10 MELANOMA"", BRITISH JOURNAL OF CANCER, vol. 74, July 1996 (1996-07-01), pages 6 - 15, XP002057838;;BELLDEGRUN ET AL: ""HUMAN RENAL CARCINOMA LINE TRANSFECTED WITH INTERLEUKIN-2 AND/OR INTERFERON ALPHA GENE(S): IMPLICATIONS FOR LIVE CANCER VACCINES"", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 85, 1993, pages 207 - 216, XP002057839;;DRANOFF ET AL: ""VACCINATION WITH IRRADIATED TUMOR CELLS ENGINEERED TO SECRETE MURINE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR STIMULATES POTENT, SPECIFIC, AND LONG-LASTING ANTI-TUMOR IMMUNITY"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES,USA, vol. 90, 1993, pages 3539 - 3543, XP002057840;;GOLUMBEK ET AL: ""CONTROLLED RELEASE, BIODEGRADABLE CYTOKINE DEPOTS: A NEW APPROACH IN CANCER VACCINE DESIGN"", CANCER RESEARCH, vol. 53, 1993, pages 5841 - 5844, XP002057841;;THOMPSON ET AL: ""SYSTEMIC AND LOCAL PARACRINE CYTOKINE THERAPIES USING TRANSDUCED TUMOR CELLS ARE SYNERGISTIC IN TREATING INTRACRANIAL TUMORS"", JOURNAL OF IMMUNOTHERAPY, vol. 19, no. 6, November 1996 (1996-11-01), pages 405 - 413, XP002057842",PENDING
42,EP,A1,EP 0930892 A1,161-963-230-935-603,1999-07-28,1999,EP 97910921 A,1997-10-15,US 9718455 W;;US 73159796 A,1996-10-16,CYTOKINE ENHANCED IMMUNOTHERAPY FOR BRAIN TUMORS,,UNIV JOHNS HOPKINS,BREM HENRY;;PARDOLL DREW M;;THOMPSON REID C;;JAFFEE ELIZABETH M;;LEONG KAM W;;EWEND MATTHEW G,,https://lens.org/161-963-230-935-603,Patent Application,yes,0,7,5,5,0,A61K9/0085;;A61K39/0011;;A61K48/00;;A61P35/00;;A61K39/0011,A61K9/50;;A61K9/00;;A61K35/12;;A61K38/00;;A61K39/00;;A61K47/30;;A61K48/00;;A61P35/00,,0,0,,,,DISCONTINUED
43,AU,A,AU 1997/048182 A,008-711-182-707-172,1998-05-11,1998,AU 1997/048182 A,1997-10-15,US 73159796 A;;US 9718455 W,1996-10-16,Cytokine enhanced immunotherapy for brain tumors,,UNIV JOHNS HOPKINS,BREM HENRY;;PARDOLL DREW M;;THOMPSON REID C;;JAFFEE ELIZABETH M;;LEONG KAM W;;EWEND MATTHEW G,,https://lens.org/008-711-182-707-172,Patent Application,no,0,0,5,5,0,A61K9/0085;;A61K39/0011;;A61K48/00;;A61P35/00;;A61K39/0011,A61K9/50;;A61K9/00;;A61K35/12;;A61K38/00;;A61K39/00;;A61K47/30;;A61K48/00;;A61P35/00,,0,0,,,,PENDING
44,US,A1,US 2008/0260834 A1,032-199-299-097-275,2008-10-23,2008,US 16503608 A,2008-06-30,US 16503608 A;;US 22368502 A,2002-08-20,VITAMIN D3 ANALOG LOADED POLYMER FORMULATIONS FOR CANCER AND NEURODEGENERATIVE DISORDERS,"Localized delivery of 1,25 D 3 directly to a target area using biodegradable polymeric matrices maximizes the efficacy of this drug while minimizing systemic exposure and toxicity. Anticalcemic analogs of 1,25 D 3 have also been incorporated into controlled release polymer formulations to achieve efficacious intracranial concentrations of 1,25 D 3 analogs for the treatment of intracranial tumors as well as neurodegenerative disorders such as Alzheimer's disease as well as to maximize the efficacy of these analogs in the treatment of systemic malignancies. The therapeutic efficacy of these formulations was demonstrated through a variety of studies in vitro and in vivo. Hybrid analogs of 1,25 D 3 were incorporated into biodegradable polymer wafers composed of a polyanhydride copolymer of 1,3-bis(p-carboxyphenoxy)propane (CPP) and sebacic acid (SA) in a 20:80 molar ratio. In addition to providing improved treatments for malignancies and neurodegenerative disorders, the spatial localization and high reproducibility of this controlled delivery methodology presents a unique opportunity to study in vivo the poorly understood mechanisms of 1,25 D 3 's antiangiogenic, antiproliferative, and transcriptional regulating activities.",BURKE MARTIN;;WHITE MARIA-CHRISTINA;;WATTS MARK C;;LEE JAE KYOO;;TYLER BETTY M;;POSNER GARY H;;BREM HENRY,BURKE MARTIN;;WHITE MARIA-CHRISTINA;;WATTS MARK C;;LEE JAE KYOO;;TYLER BETTY M;;POSNER GARY H;;BREM HENRY,,https://lens.org/032-199-299-097-275,Patent Application,yes,10,1,1,1,0,A61K9/0024;;A61K9/0085;;A61K9/1641;;A61K9/0024;;A61K9/1641;;A61K9/0085,A61K31/59;;A61K9/00;;A61K9/10;;A61K9/16;;A61P25/28;;A61P35/00,424/486;;514/167,0,0,,,,DISCONTINUED
45,AU,A,AU 1998/093769 A,050-920-472-822-949,1999-03-22,1999,AU 1998/093769 A,1998-09-02,US 5743697 P;;US 9818425 W,1997-09-02,Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders,,UNIV JOHNS HOPKINS SCHOOL MEDICINE,BURKE MARTIN;;WHITE MARIA CHRISTINA;;WATTS MARK C;;LEE JAE KYOO;;TYLER BETTY M;;POSNER GARY H;;BREM HENRY,,https://lens.org/050-920-472-822-949,Patent Application,no,0,0,4,4,0,A61K9/0024;;A61K9/0085;;A61K9/1641;;A61K9/0024;;A61K9/0085;;A61K9/1641,A61K9/00;;A61K9/16,,0,0,,,,DISCONTINUED
46,WO,A1,WO 1999/011272 A1,037-241-758-108-681,1999-03-11,1999,US 9818425 W,1998-09-02,US 5743697 P,1997-09-02,VITAMIN D3 ANALOG LOADED POLYMER FORMULATIONS FOR CANCER AND NEURODEGENERATIVE DISORDERS,"Localized delivery of 1,25 D3 directly to a target area using biodegradable polymeric matrices maximizes the efficacy of this drug while minimizing systemic exposure and toxicity. Anticalcemic analogs of 1,25 D3 have also been incorporated into controlled release polymer formulations to achieve efficacious intracranial concentrations of 1,25 D3 analogs for the treatment of intracranial tumors as well as neurodegenerative disorders such as Alzheimer's disease as well as to maximize the efficacy of these analogs in the treatment of systemic malignancies. The therapeutic efficacy of these formulations was demonstrated through a variety of studies in vitro and in vivo. Hybrid analogs of 1,25 D3 were incorporated into biodegradable polymer wafers composed of a polyanhydride copolymer of 1,3-bis(p-carboxyphenoxy)propane (CPP) and sebacic acid (SA) in a 20:80 molar ratio. In addition to providing improved treatments for malignancies and neurodegenerative disorders, the spatial localization and high reproducibility of this controlled delivery methodology presents a unique opportunity to study in vivo the poorly understood mechanisms of 1,25 D3's antiangiogenic, antiproliferative, and transcriptional regulating activities.",UNIV JOHNS HOPKINS MED,BURKE MARTIN;;WHITE MARIA CHRISTINA;;WATTS MARK C;;LEE JAE KYOO;;TYLER BETTY M;;POSNER GARY H;;BREM HENRY,,https://lens.org/037-241-758-108-681,Patent Application,yes,3,32,4,4,0,A61K9/0024;;A61K9/0085;;A61K9/1641;;A61K9/0024;;A61K9/0085;;A61K9/1641,A61K9/00;;A61K9/16,,5,0,,,"CHEMICAL ABSTRACTS, vol. 127, no. 19, 10 November 1997, Columbus, Ohio, US; abstract no. 257698, XP002089220;;CHEMICAL ABSTRACTS, vol. 126, no. 23, 9 June 1997, Columbus, Ohio, US; abstract no. 305672, XP002089221;;CHEMICAL ABSTRACTS, vol. 122, no. 9, 27 February 1995, Columbus, Ohio, US; abstract no. 97134, XP002089222;;CHEMICAL ABSTRACTS, vol. 117, no. 11, 14 September 1992, Columbus, Ohio, US; abstract no. 111890, XP002089223;;CHEMICAL ABSTRACTS, vol. 122, no. 14, 3 April 1995, Columbus, Ohio, US; abstract no. 169978, XP002089224",PENDING
47,US,A1,US 2002/0076442 A1,193-181-847-633-378,2002-06-20,2002,US 14586798 A,1998-09-02,US 14586798 A;;US 5743697 P,1997-09-02,VITAMIN D3 ANALOG LOADED POLYMER FORMULATIONS FOR CANCER AND NEURODEGENERATIVE DISORDERS,"
    Localized delivery of 1,25 D ₃ directly to a target area using biodegradable polymeric matrices maximizes the efficacy of this drug while minimizing systemic exposure and toxicity. Anticalcemic analogs of 1,25 D ₃ have also been incorporated into controlled release polymer formulations to achieve efficacious intracranial concentrations of 1,25 D ₃ analogs for the treatment of intracranial tumors as well as neurodegenerative disorders such as Alzheimer's disease as well as to maximize the efficacy of these analogs in the treatment of systemic malignancies. The therapeutic efficacy of these formulations was demonstrated through a variety of studies in vitro and in vivo. Hybrid analogs of 1,25 D ₃ were incorporated into biodegradable polymer wafers composed of a polyanhydride copolymer of 1,3-bis(p-carboxyphenoxy)propane (CPP) and sebacic acid (SA) in a 20:80 molar ratio. In addition to providing improved treatments for malignancies and neurodegenerative disorders. the spatial localization and high reproducibility of this controlled delivery methodology presents a unique opportunity to study in vivo the poorly understood mechanisms of 1,25 D ₃ 's antiangiogenic, antiproliferative, and transcriptional regulating activities. 
",BURKE MARTIN;;WHITE MARIA-CHRISTINA;;WATTS MARK C.;;LEE JAE KYOO;;TYLER BETTY M.;;POSNER GARY H.;;BREM HENRY,BURKE MARTIN;;WHITE MARIA-CHRISTINA;;WATTS MARK C;;LEE JAE KYOO;;TYLER BETTY M;;POSNER GARY H;;BREM HENRY,JOHNS HOPKINS UNIVERSITY (1998-11-19),https://lens.org/193-181-847-633-378,Patent Application,yes,0,20,4,4,0,A61K9/0024;;A61K9/0085;;A61K9/1641;;A61K9/0024;;A61K9/0085;;A61K9/1641,A61K9/00;;A61K9/16,424/486;;514/179;;424/426;;424/428,0,0,,,,DISCONTINUED
48,US,A1,US 2003/0105067 A1,172-035-108-146-173,2003-06-05,2003,US 22368502 A,2002-08-20,US 22368502 A;;US 14586798 A;;US 5743697 P,1997-09-02,Vitamin D3 analog loaded polymer formulations for cancer and neurodegenerative disorders,"
    Localized delivery of 1,25 D ₃ directly to a target area using biodegradable polymeric matrices maximizes the efficacy of this drug while minimizing systemic exposure and toxicity. Anticalcemic analogs of 1,25 D ₃ have also been incorporated into controlled release polymer formulations to achieve efficacious intracranial concentrations of 1,25 D ₃ analogs for the treatment of intracranial tumors as well as neurodegenerative disorders such as Alzheimer's disease as well as to maximize the efficacy of these analogs in the treatment of systemic malignancies. The therapeutic efficacy of these formulations was demonstrated through a variety of studies in vitro and in vivo. Hybrid analogs of 1,25 D ₃ were incorporated into biodegradable polymer wafers composed of a polyanhydride copolymer of 1,3-bis(p-carboxyphenoxy)propane (CPP) and sebacic acid (SA) in a 20:80 molar ratio. In addition to providing improved treatments for malignancies and neurodegenerative disorders, the spatial localization and high reproducibility of this controlled delivery methodology presents a unique opportunity to study in vivo the poorly understood mechanisms of 1,25 D ₃ 's antiangiogenic, antiproliferative, and transcriptional regulating activities. 
",UNIV JOHNS HOPKINS,BURKE MARTIN;;WHITE MARIA-CHRISTINA;;WATTS MARK C;;LEE JAE KYOO;;TYLER BETTY M;;POSNER GARY H;;BREM HENRY,POSNER GARY H (2007-01-31);;LEE JAE KYOO (2007-01-31);;TYLER BETTY M (2007-01-31);;WATTS MARK C (2007-01-31);;WHITE MARIA-CHRISTINA (2007-01-31);;BURKE MARTIN (2007-01-31);;BREM HENRY (2007-01-31),https://lens.org/172-035-108-146-173,Patent Application,yes,10,1,4,4,0,A61K9/0024;;A61K9/0085;;A61K9/1641;;A61K9/0024;;A61K9/0085;;A61K9/1641,A61K9/00;;A61K9/16,514/167;;424/486,0,0,,,,DISCONTINUED
